Sheffield Hallam University

The prevalence of onchocerciasis in Africa and Yemen, 2000–2018: a geospatial analysis

SCHMIDT, C.A., CROMWELL, E.A., HILL, E., DONKERS, K.M., SCHIPP, M.F., JOHNSON, K.B., PIGOTT, D.M., LBD 2019 NEGLECTED TROPICAL DISEASES COLLABORATORS, and HAY, Simon I.

Published version

Copyright and re-use policy

1 **Additional File 1:** Supplementary Appendix for *The prevalence of onchocerciasis in Africa*
2 *and Yemen, 2000–2018: A geospatial analysis*

3 ## Contents

64

65

66

67 **List of Supplementary Figures**

82

83 **List of Supplementary Tables**

96

1.0 GATHER compliance

Supplementary Table 1. Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) checklist.

Item #	Checklist item	Reported on page #
Objectives and Funding		
1	Define the indicator(s), populations (including age, sex, and geographic entities), and time period(s) for which estimates were made.	Main Text: Introduction, Methods (Data inputs); Methods (Covariates)
2	List the funding sources for the work.	Main text: Acknowledgments
Data Inputs		
For all data inputs from multiple sources that are synthesized as part of the study:		
3	Describe how the data were identified and how the data were accessed.	Main Text: Methods (Data inputs); Supplementary Information: 3.2 Systematic review
4	Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions.	Main Text: Methods (Data inputs); 3.0 Supplementary data; Supplementary Information: 3.2 Systematic review
5	Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant.	Supplementary Information: 3.0 Supplementary data
6	Identify and describe any categories of input data that have potentially important biases (e.g., based on characteristics listed in item 5).	Main text: Discussion (Limitations)
For data inputs that contribute to the analysis but were not synthesized as part of the study:		
7	Describe and give sources for any other data inputs.	Main text: Methods (Geospatial covariates), Supplementary Information: 4.0 Supplementary covariates
For all data inputs:		
8	Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data.	Available at (GHDx link will be added upon review) Supplementary Information: 3.0 Supplementary data
9	Provide a conceptual overview of the data analysis method. A diagram may be helpful.	Main text: Methods (Age and diagnostic adjustment), Supplementary Information: 5.1 Age and diagnostic crosswalks; Supplementary Information: Table 6: data used in estimation of age and diagnostic crosswalk
10	Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data pre-processing, data adjustments and weighting of data sources, and mathematical or statistical model(s).	Main text: Methods (Geospatial analysis), Supplementary Information: 5.3 Geostatistical model
11	Describe how candidate models were evaluated and how the final model(s) were selected.	Main text: Methods (Geospatial analysis), Supplementary Information: 5.4 Model validation
12	Provide the results of an evaluation of model performance, if done, as well as the results of any relevant sensitivity analysis.	Main text: Methods (Geospatial analysis), Supplementary Information: 5.4 Model validation
13	Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and were not, accounted for in the uncertainty analysis.	Main text: Methods (Geospatial analysis), Supplementary Information: 5.3.4. Model description
14	State how analytic or statistical source code used to generate estimates can be accessed.	Available at (GHDx link will be added upon review)
Results and Discussion		
15	Provide published estimates in a file format from which data can be efficiently extracted.	Raster files for spatial data and CSVs of estimates available at (GHDx link will be added upon review)
16	Report a quantitative measure of the uncertainty of the estimates (e.g., uncertainty intervals).	Supplementary Information: Supplementary Figure 11 and Table 9

4

17	Interpret results in light of existing evidence. If updating a previous set of estimates, describe the reasons for changes in estimates.	Main text: Discussion (Strengths)
18	Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data limitations that affect interpretation of the estimates.	Main text: Discussion (Limitations)

101

2.0 Supplementary discussion

This document outlines the major data processing, modelling, and validation steps for the onchocerciasis prevalence analysis described in the main text (Supplementary Figure 1). We present a detailed description of model inputs, including data coverage, covariate sources, and geo-referencing. The geospatial model is described along with model validation metrics.

108
Supplementary Figure 1. Flowchart of major steps in data processing and modelling of onchocerciasis prevalence.

3.0 Supplementary data

In the following section, we present a detailed summary of the data inputs used to estimate the prevalence of onchocerciasis in Africa and Yemen. Broadly, we aimed to include all published sources of onchocerciasis infection prevalence, as well as routine programme monitoring data collected to monitor progress toward onchocerciasis elimination. Data inputs were retained for analysis if they could be accurately geo-referenced.

3.1 Geographical restrictions

Supplementary Table 2 lists all countries included in our MBG (model-based geostatistical) modelling region. Inclusion was partially based on ESPEN (Expanded Special Project for Elimination of Neglected Tropical Diseases)

5

120 onchocerciasis endemicity classifications,(1) with extensions to some neighbouring countries outside the WHO
121 (World Health Organization) AFRO (Regional Office for Africa) region which have evidence of onchocerciasis
122 endemicity or uncertain endemicity status (Sudan, Somalia, and Yemen). Portions of Mauritius, Namibia, and
123 Zambia are considered by ESPEN as candidates for future elimination mapping but were not included in our
124 geospatial model. Conversely, The Gambia is considered non-endemic but we included it in our model for
125 geographical continuity. Countries in the Americas with historical or residual onchocerciasis burdens were not
126 modelled due to their highly localised endemicity.

127 **Supplementary Table 2. Geographical restrictions.**

128 The geographical definition of the modelling region is indicated, with country-level onchocerciasis endemicity
129 status per ESPEN, and which countries were included in our geospatial analysis from 2000 to 2018. Endemicity
130 classifications were derived from ESPEN data at the level of intervention units (IU) (retrieved 14 February 2020).
131 Countries outside the WHO AFRO region are not covered by the scope of ESPEN; countries in the WHO EMRO
132 (Eastern Mediterranean Regional Office) region are listed here if they are in Africa or have evidence of
133 onchocerciasis endemicity or uncertain status. We considered countries endemic if they had at least one intervention
134 unit that was flagged as endemic by ESPEN. Number of observations: The number of data rows in the final dataset
135 for a given country.
136

Location	ESPEN endemicity	Included in 2000–2018 model?	Number of Observations
AFRO(1)			
Algeria	Non-endemic	no	-
Angola	Endemic	yes	876
Benin	Endemic	yes	300
Botswana	Non-endemic	no	-
Burkina Faso	Endemic	yes	72
Burundi	Endemic	yes	263
Cabo Verde	Non-endemic	no	-
Cameroon	Endemic	yes	1216
Central African Republic	Endemic	yes	1079
Chad	Endemic	yes	753
Comoros	Non-endemic	no	-
Republic of the Congo	Endemic	yes	490
Côte d'Ivoire	Endemic	yes	95
Democratic Republic of the Congo	Endemic	yes	4574
Equatorial Guinea	Endemic	yes	341
Eritrea	Non-endemic	no	-
Eswatini	Non-endemic	no	-

6

Location	ESPEN endemicity	Included in 2000–2018 model?	Number of Observations
Ethiopia	Endemic	yes	1062
Gabon	Endemic	yes	157
The Gambia	Non-endemic	yes	0
Ghana	Endemic	yes	78
Guinea	Endemic	yes	193
Guinea-Bissau	Endemic	yes	0
Kenya	Consider oncho elimination mapping	yes	94
Lesotho	Non-endemic	no	-
Liberia	Endemic	yes	114
Madagascar	Non-endemic	no	-
Malawi	Endemic	yes	333
Mali	Endemic	yes	160
Mauritania	Non-endemic	no	-
Mauritius	Mapping gap (one district)	no	-
Mozambique	Endemic	yes	291
Namibia	Consider oncho elimination mapping (some districts)	no	-
Niger	Endemic	yes	0
Nigeria	Endemic	yes	3445
Rwanda	Consider oncho elimination mapping	yes	90
São Tomé and Príncipe	Non-endemic	yes	0
Senegal	Endemic	yes	67
Seychelles	Non-endemic	no	-
Sierra Leone	Endemic	yes	223
South Africa	Non-endemic	no	-
South Sudan	Endemic	yes	466
Togo	Endemic	yes	160
Uganda	Endemic	yes	620
Tanzania	Endemic	yes	478

Location	ESPEN endemicity	Included in 2000–2018 model?	Number of Observations
Zambia	Consider oncho elimination mapping (some districts)	no	-
Zimbabwe	Non-endemic	no	-
EMRO(2)			
Djibouti	-	no	-
Egypt	-	no	-
Libya	-	no	-
Morocco	-	no	-
Somalia	-	yes	0
Sudan	(Endemic)	yes	26
Tunisia	-	no	-
Yemen	(Endemic)	yes	0

3.2 Systematic review

Articles related to onchocerciasis were found by searching PubMed, Scopus, and Web of Science using the following keywords: "Oncho", "river blindness", "O. Volvulus", "robles disease", "blinding filariasis", "coast erysipelas", and "sowda". A systematic review of these reports, all published before July 7, 2017, was then conducted. A second round of formal reviews was undertaken on June 6, 2019, to cover new articles published after July 7, 2017, and followed the same process as the first round.

3.2.1 Systematic review data processing

The systematic review process is illustrated in Supplementary Figure 2. Throughout the systematic review we excluded publications that met the following criteria: no measurement of onchocerciasis prevalence, data collected before 1985, case-control studies, qualitative research publications, duplicative data from cohort studies, hospital-based studies, and publications that did not report the location of data collection. The search identified 4048 publications, which were reduced to 579 after screening titles and abstracts. A full-text review was completed for the remaining publications. The full-text review yielded 259 publications which met the inclusion criteria and were extracted. The literature review was updated on June 6, 2019, by searching PubMed with the same search string used in 2017 for articles published after July 7, 2017. The search returned 304 results, which were narrowed to 115 articles after screening titles and abstracts. A full-text review resulted in 22 articles that were eligible for extraction. Additional publications were identified outside of the literature review and screened for inclusion by the same criteria, up through April 14, 2020. The final dataset drew from 290 articles. Overall, 16 096 datapoints were extracted and geo-located from 290 publications. Data extracted from each source included survey year, age-range of individuals tested, diagnostic information, sample size, number of individuals tested positive, and sampling strategy details.

Supplementary Figure 2. Onchocerciasis article review and data extraction flowchart.

Each step of the extraction process is outlined, from article identification and screening to extraction, including the number of articles or records that were processed or removed in each step before reaching the final dataset. Additional articles outside of the literature review were identified and screened for inclusion ("ongoing process") on an ongoing basis up until April 14, 2020.

3.3 Geo-positioning

Geographical information associated with onchocerciasis prevalence data were verified and geo-located to ensure accuracy. Data associated with locations smaller than 5×5 km were treated as points and geo-located as latitude/longitude coordinates. Coordinates provided by a data source were mapped to ensure that the coordinates were located in the correct administrative units. If coordinates were not reported, points were geolocated and vetted by comparing results from Google Maps, Fuzzy Gazetteer, Geonames, and Open Street Map. Locations larger than 5×5 km were treated as polygon data and geo-located to the most granular administrative boundary possible (most commonly district level). Custom shapefiles were created to geolocate areas that did not align with administrative boundaries. In the event that a literature source only included a map of locations sampled without any other information, ArcGIS software was utilised to overlay the map onto existing administrative boundaries, and location coordinates or custom polygons were manually created and recorded. Prevalence data that were reported for administrative areas were matched to their appropriate polygon by searching our administrative shapefile database. If place names were unidentifiable across multiple shapefile libraries or geo-referencing sources, they were excluded from the analysis.

3.4 Data processing

Data were excluded from the analysis for the following reasons: did not report survey year (N = 8236); did not report post-1988 data (N = 2648); did not report skin snip microscopy or nodule prevalence (N = 12 121); did not report sample size or prevalence (N = 30); or did not report data for countries in the modelling region or could not be accurately georeferenced (N = 580). Duplicate records were identified and excluded (N = 1592); these generally reflected different data sources (eg, literature extraction and ESPEN) which contained the same survey, as judged by identical year, location, sample size, cases, and reference when available, although there was some deduplication within individual data sources. Prior to polygon resampling (see section 5.2), the dataset consisted of 18 116 georeferenced prevalence observations, consisting of 17 896 point-referenced observations and 220 areal observations. A total of 14 314 observations represented prevalence based on nodule examinations, and 3802 observations represented microfiladermia prevalence as measured by skin snip assays. After resampling, the full modelling dataset consisted of 20 124 georeferenced datapoints.

Supplementary Table 3 provides citations for data sources used in our onchocerciasis MBG model. The geographical coverage of the final dataset is summarised in Supplementary Figure 3.

199 **Supplementary Table 3. Citations for data inputs.**

200 The NID is a unique identifier cataloguing all data inputs in the Global Health Data Exchange
201 (http://ghdx.healthdata.org). Note: Records are listed here in alphabetical order by geography, but some sources
202 provided data for multiple countries; such sources are listed here only once.
203

NID	Geographies	Citation
332798	Angola	Carme B, Ntsoumou-Madzou V, Samba Y, Yebakima A. Prevalence of depigmentation of the shins: a simple and cheap way to screen for severe endemic onchocerciasis in Africa. Bull World Health Organ. 1993; 71(6): 755–8.
334477	Benin	Gallin M, Adams A, Kruppa TF, Gbaguidi EA, Massougbodji A, Sadeler BC, Brattig N, Erttmann KD. Epidemiological studies of onchocerciasis in southern Benin. Trop Med Parasitol. 1993; 44(2): 69–74.
125405	Burkina Faso	Kabore JK, Cabore JW, Melaku Z, Druet-Cabanac M, Preux PM. Epilepsy in a focus of onchocerciasis in Burkina Faso. Lancet. 1996; 347(9004): 836.
334475	Burkina Faso	De Sole G, Remme J. Importance of migrants infected with Onchocerca volvulus in west African river valleys protected by 14 to 15 years of Simulium control. Trop Med Parasitol. 1991; 42(2): 75–8.
332903	Burkina Faso, Côte d'Ivoire	Toè L, Adjami AG, Boatin BA, Back C, Alley ES, Dembélé N, Brika PG, Pearlman E, Unnasch TR. Topical application of diethylcarbamazine to detect onchocerciasis recrudescence in west Africa. Trans R Soc Trop Med Hyg. 2000; 94(5): 519–25.
334481	Burundi	Newell E d. Comparison of the use of skin scarification and skin biopsies to determine the prevalence and intensity of Onchocerca volvulus infection. Ann Trop Med Parasitol. 1997; 91(6): 633.
338571	Burundi	Newell ED, Hicuburundi B, Ndimuruvugo N. [Endemicity and clinical manifestations of onchocerciasis in the province of Bururi, Burundi]. Trop Med Int Health. 1997; 2(3): 218–26.
338573	Burundi	Newell ED, Ndimuruvugo N, Nimpa D. [Endemicity and clinical manifestations of onchocerciasis in the provinces of Cibitoke and Bubanza (Burundi)]. Bull Soc Pathol Exot. 1997; 90(5): 353–7.
136492	Cameroon	Cho-Ngwa F, Amambua AN, Ambele MA, Titanji VPK. Evidence for the exacerbation of lymphedema of geochemical origin, podoconiosis, by onchocerciasis. J Infect Public Health. 2009; 2(4): 198-203.
159316	Cameroon	Matthews GA, Dobson HM, Nkot PB, Wiles TL, Birchmore M. Preliminary examination of integrated vector management in a tropical rainforest area of Cameroon. Trans R Soc Trop Med Hyg. 2009; 103(11): 1098-104.
324729	Cameroon	Kamga G-R, Dissak-Delon FN, Nana-Djeunga HC, Biholong BD, Mbigha-Ghogomu S, Souopgui J, Zoure HGM, Boussinesq M, Kamgno J, Robert A. Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment. Parasites Vectors. 2016; 9(1): 581.
327960	Cameroon	Wanji S, Kengne-Ouafo JA, Esum ME, Chounna PWN, Tendongfor N, Adzemye BF, Eyong JEE, Jato I, Datchoua-Poutcheu FR, Kah E, Enyong P, Taylor DW. Situation analysis of parasitological and entomological indices of onchocerciasis transmission in three drainage basins of the rain forest of South West Cameroon after a decade of ivermectin treatment. Parasites Vectors. 2015; 8: 202.
327968	Cameroon	Katabarwa MN, Eyamba A, Chouaibou M, Enyong P, Kuété T, Yaya S, Yougouda A, Baldiagaï J, Madi K, Andze GO, Richards F. Does onchocerciasis transmission take place in hypoendemic areas? a study from the North Region of Cameroon. Trop Med Int Health. 2010; 15(5): 645-52.

10

NID	Geographies	Citation
327992	Cameroon	Katabarwa MN, Eyamba A, Nwane P, Enyong P, Kamgno J, Kueté T, Yaya S, Aboutou R, Mukenge L, Kafando C, Siaka C, Mkpouwoueiko S, Ngangue D, Biholong BD, Andze GO. Fifteen years of annual mass treatment of onchocerciasis with ivermectin have not interrupted transmission in the west region of cameroon. J Parasitol Res. 2013; 2013: 420928.
328065	Cameroon	Katabarwa MN, Eyamba A, Nwane P, Enyong P, Yaya S, Baldiagaï J, Madi TK, Yougouda A, Andze GO, Richards FO. Seventeen years of annual distribution of ivermectin has not interrupted onchocerciasis transmission in North Region, Cameroon. Am J Trop Med Hyg. 2011; 85(6): 1041-9.
328095	Cameroon	Kamga HLF, Shey DN, Assob JCN, Njunda AL, Nde Fon P, Njem PK. Prevalence of onchocerciasis in the Fundong Health District, Cameroon after 6 years of continuous community-directed treatment with ivermectin. Pan Afr Med J. 2011; 10: 34.
332745	Cameroon	Pion SDS, Clarke P, Filipe J a. N, Kamgno J, Gardon J, Basáñez M-G, Boussinesq M. Co-infection with Onchocerca volvulus and Loa loa microfilariae in central Cameroon: are these two species interacting?. Parasitology. 2006; 132(Pt 6): 843–54.
332783	Cameroon	Boussinesq M, Chippaux JP, Ernould JC, Quillevere D, Prod'hon J. Effect of repeated treatments with ivermectin on the incidence of onchocerciasis in northern Cameroon. Am J Trop Med Hyg. 1995; 53(1): 63–7.
332786	Cameroon	Kollo B, Mather FJ, Cline BL. Evaluation of alternate methods of rapid assessment of endemicity of Onchocerca volvulus in communities in southern Cameroon. Am J Trop Med Hyg. 1995; 53(3): 243–7.
332788	Cameroon	Ngoumou P, Walsh JF, Mace JM. A rapid mapping technique for the prevalence and distribution of onchocerciasis: a Cameroon case study. Ann Trop Med Parasitol. 1994; 88(5): 463–74.
332790	Cameroon	Mendoza Aldana J, Piechulek H, Maguire J. Forest onchocerciasis in Cameroon: its distribution and implications for selection of communities for control programmes. Ann Trop Med Parasitol. 1997; 91(1): 79–86.
332840	Cameroon	Ayong LS, Tume CB, Wembe FE, Simo G, Asonganyi T, Lando G, Ngu JL. Development and evaluation of an antigen detection dipstick assay for the diagnosis of human onchocerciasis. Trop Med Int Health. 2005; 10(3): 228-33.
332848	Cameroon	Wanji S, Tendongfor N, Esum M, Ndindeng S, Enyong P. Epidemiology of concomitant infections due to Loa loa, Mansonella perstans, and Onchocerca volvulus in rain forest villages of Cameroon. Med Microbiol Immunol. 2003; 192(1): 15-21.
332893	Cameroon	Kamgno J, Boussinesq M. [Hyperendemic loaiasis in the Tikar plain, shrub savanna region of Cameroon]. Bull Soc Pathol Exot. 2001; 94(4): 342–6.
332897	Cameroon	Esum M, Wanji S, Tendongfor N, Enyong P. Co-endemicity of loiasis and onchocerciasis in the South West Province of Cameroon: implications for mass treatment with ivermectin. Trans R Soc Trop Med Hyg. 2001; 95(6): 673–6.
338584	Cameroon	Kamgno J, Bouchité B, Baldet T, Folefack G, Godin C, Boussinesq M. [Study of the distribution of human filariasis in West Province of Cameroon]. Bull Soc Pathol Exot. 1997; 90(5): 327–30.
332820	Cameroon, Central African Republic, Gabon	Ozoh G, Boussinesq M, Bissek A-CZ-K, Kobangue L, Kombila M, Mbina J-RM, Enyong P, Noma M, Sékétéli A, Fobi G. Evaluation of the diethylcarbamazine patch to evaluate onchocerciasis endemicity in Central Africa. Trop Med Int Health. 2007; 12(1): 123-9.

11

| NID	Geographies	Citation
327872	Cameroon, Nigeria, Sudan, Uganda	Ozoh GA, Murdoch ME, Bissek A-C, Hagan M, Ogbuagu K, Shamad M, Braide EI, Boussinesq M, Noma MM, Murdoch IE, Sékétéli A, Amazigo UV. The African Programme for Onchocerciasis Control: impact on onchocercal skin disease. Trop Med Int Health. 2011; 16(7): 875–83.
332855	Central African Republic	Kennedy MH, Bertocchi I, Hopkins AD, Meredith SE. The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Ann Trop Med Parasitol. 2002; 96(3): 297-307.
332796	Congo	Brito M, Paulo R, Van-Dunem P, Martins A, Unnasch TR, Novak RJ, Jacob B, Stanton MC, Molyneux DH, Kelly-Hope LA. Rapid Integrated Clinical Survey to Determine Prevalence and Co-distribution Patterns of Lymphatic Filariasis and Onchocerciasis in a Loa Loa Co-endemic Area: The Angolan Experience. Parasite Epidemiol Control. 2017; 2(3): 71-84.
338569	Congo	Talani P, Missamou F, Kankou JM, Niabe B, Obengui null, Moyen G. [Rapid epidemiological mapping of onchocerciasis in Congo Brazzaville]. Dakar Med. 2005; 50(3): 164–7.
327962	Côte d'Ivoire	Lloyd MM, Gilbert R, Taha NT, Weil GJ, Meite A, Kouakou IMM, Fischer PU. Conventional parasitology and DNA-based diagnostic methods for onchocerciasis elimination programmes. Acta Trop. 2015; 146: 114-8.
338588	Côte d'Ivoire	Diarrassouba S, Traore S, Riviere F. [Endemic onchocerciasis in forested zones of Ivory Coast: prevalence rate and microfilarial densities]. Med Trop (Mars). 1996; 56(1): 59–62.
332853	Democratic Republic of Congo	Kayembe DL, Kasonga DL, Kayembe PK, Mwanza J-CK, Boussinesq M. Profile of eye lesions and vision loss: a cross-sectional study in Lusambo, a forest-savanna area hyperendemic for onchocerciasis in the Democratic Republic of Congo. Trop Med Int Health. 2003; 8(1): 83-9.
327885	Ethiopia	Feleke SM, Tadesse G, Mekete K, Tekle AH, Kebede A. Epidemiological Mapping of Human Onchocerciasis in Transmission Suspected Districts of Bale, Borena, and West Arsi Zones of Eastern Ethiopia. Interdiscip Perspect Infect Dis. 2016; 2016: 6937509.
327957	Ethiopia	Dana D, Debalke S, Mekonnen Z, Kassahun W, Suleman S, Getahun K, Yewhalaw D. A community-based cross-sectional study of the epidemiology of onchocerciasis in unmapped villages for community directed treatment with ivermectin in Jimma Zone, southwestern Ethiopia. BMC Public Health. 2015; 15: 595.
328057	Ethiopia	Dori GU, Belay T, Belete H, Panicker KN, Hailu A. Parasitological and clinico-epidemiological features of onchocerciasis in West Wellega, Ethiopia. J Parasit Dis. 2012; 36(1): 10-8.
332186	Ethiopia	Mengistu G, Balcha F, Britton S. Co-infection of Onchocerca volvulus and intestinal helminths in indigenous and migrant farmers in southwest Ethiopia. Ethiop Med J. 2002; 40(1): 19–27.
332189	Ethiopia	Jira C. Prevalence of onchocerciasis in Blue Nile valley of western Ethiopia. Indian J Public Health. 1993; 37(4): 135–7.
332193	Ethiopia	Taye A, Gebre-Michael T, Taticheff S. Onchocerciasis in Gilgel Ghibe River Valley southwest Ethiopia. East Afr Med J. 2000; 77(2): 116–20.
332674	Ethiopia	Adugna N, Woldegiorgis M, Tilahun D, Kebede A, Hadis M. The Epidemiology of Onchocerciasis in the Resettled and Indigenous Population in Pawe, Western Ethiopia. Ethiop Med J. 1999; 37(1): 41-50.

NID	Geographies	Citation
332676	Ethiopia	Legesse M, Balcha F, Erko B. Status of onchocerciasis in Teppi area, Southwestern Ethiopia, after four years of annual community-directed treatment with ivermectin. Ethiop J Health Dev. 2010; 24(1): 51-56.
332678	Ethiopia	Samuel A, Belay T, Yehalaw D, Taha M, Zemene E, Zeynudin A. Impact of Six Years Community Directed Treatment with Ivermectin in the Control of Onchocerciasis, Western Ethiopia. PLoS One. 2016; 11(3): e0141029.
332851	Ethiopia	Hailu A, Balcha F, Birrie H, Berhe N, Aga A, Mengistu G, Bezuneh A, Ali A, Gebre-Michael T, Gemetchu T. Prevalence of onchocercal skin disease and infection among workers of coffee plantation farms in Teppi, southwestern Ethiopia. Ethiop Med J. 2002; 40(3): 259-69.
332825	Gabon	Fobi G, Mourou Mbina JR, Ozoh G, Kombila M, Agaya C, Olinga Olinga JM, Boussinesq M, Enyong P, Noma M, Sékétéli A. [Onchocerciasis in the area of Lastourville, Gabon. Clinical and entomological aspects]. Bull Soc Pathol Exot. 2006; 99(4): 269-71.
327974	Ghana	Garms R, Badu K, Owusu-Dabo E, Baffour-Awuah S, Adjei O, Debrah AY, Nagel M, Biritwum NK, Gankpala L, Post RJ, Kruppa TF. Assessments of the transmission of Onchocerca volvulus by Simulium sanctipauli in the Upper Denkyira District, Ghana, and the intermittent disappearance of the vector. Parasitol Res. 2015; 114(3): 1129-37.
327912	Ghana, Sri Lanka	Frempong KK, Walker M, Cheke RA, Tetevi EJ, Gyan ET, Owusu EO, Wilson MD, Boakye DA, Taylor MJ, Biritwum N-K, Osei-Atweneboana M, Basáñez M-G. Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?. Clin Infect Dis. 2016; 62(11): 1338–47.
332662	Malawi, Tanzania	Courtright P, Johnston K, Chitsulo L. A new focus of onchocerciasis in Mwanza District, Malawi. Trans R Soc Trop Med Hyg. 1995; 89(1): 34–6.
144330	Mali, Senegal	Diawara L, Traoré MO, Badji A, Bissan Y, Doumbia K, Goita SF, Konaté L, Mounkoro K, Sarr MD, Seck AF, Toé L, Tourée S, Remme JH. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis. 2009; 3(7): e497.
191825	Mali, Senegal	Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, Goita SF, Konate L, Mounkoro K, Seck AF, Toe L, Toure S, Remme JH. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis. 2012; 6(9): e1825.
136520	Nigeria	Anosike JC, Onwuliri CO. Studies on filariasis in Bauchi State, Nigeria. II. The prevalence of human filariasis in Darazo Local Government area. Appl Parasitol. 1994; 35(4): 242-50.
147655	Nigeria	Anosike JC, Onwuliri COE, Onwuliri VA. Human filariasis in Dass local government area of Bauchi state, Nigeria. Trop Ecol. 2003; 44(2): 217-27.
147869	Nigeria	Uttah E, Ibeh DC. Multiple filarial species microfiladermia: a comparative study of areas with endemic and sporadic onchocerciasis. J Vector Borne Dis. 2011; 48(4): 197-204.
324133	Nigeria	Evans DS, Alphonsus K, Umaru J, Eigege A, Miri E, Mafuyai H, Gonzales-Peralta C, Adamani W, Pede E, Umbugadu C, Saka Y, Okoeguale B, Richards FO. Status of Onchocerciasis transmission after more than a decade of mass drug administration for onchocerciasis and lymphatic filariasis elimination in central Nigeria: challenges in coordinating the stop MDA decision. PLoS Negl Trop Dis. 2014; 8(9): 1-10.

NID	Geographies	Citation
327876	Nigeria	Eyo J, Onyishi G, Ugokwe C. Rapid epidemiological assessment of onchocerciasis in a tropical semi-urban community, enugu state, Nigeria. Iran J Parasitol. 2013; 8(1): 145–51.
327921	Nigeria	Katabarwa M, Eyamba A, Habomugisha P, Lakwo T, Ekobo S, Kamgno J, Kuete T, Ndyomugyenyi R, Onapa A, Salifou M, Ntep M, Richards FO. After a decade of annual dose mass ivermectin treatment in Cameroon and Uganda, onchocerciasis transmission continues. Trop Med Int Health. 2008; 13(9): 1196-1203.
327941	Nigeria	Okoye IC, Onwuliri CO. Epidemiology and psycho-social aspects of onchocercal skin diseases in northeastern Nigeria. Filaria J. 2007; 6: 15.
327954	Nigeria	Okoye IC, Onwuliri CO. Epidemiology and psycho-social aspects of onchocercal skin diseases in northeastern Nigeria. Filaria J. 2007; 6: 15.
327966	Nigeria	Ojurongbe O, Akindele AA, Adeleke MA, Oyedeji MO, Adedokun SA, Ojo JF, Akinleye CA, Bolaji OS, Adefioye OA, Adeyeba OA. Co-endemicity of loiasis and onchocerciasis in rain forest communities in southwestern Nigeria. PLoS Negl Trop Dis. 2015; 9(3): e0003633.
327972	Nigeria	Opara KN, Fagbemi BO. Population dynamics of onchocerca volvulus microfilariae in human host after six years of drug control. J Vector Borne Dis. 2008; 45(1): 29-37.
327982	Nigeria	Akinbo FO, Okaka CE. Hyperendemicity of onchocerciasis in Ovia Northeast Local Government Area, Edo State, Nigeria. East Afr J Public Health. 2010; 7(1): 84-6.
328059	Nigeria	Osue HO, Inabo HI, Yakubu SE, Audu PA, Galadima M, Odama LE, Musa D, Ado SA, Mamman M. Impact of Eighteen-Year Varied Compliance to Onchocerciasis Treatment with Ivermectin in Sentinel Savannah Agrarian Communities in Kaduna State of Nigeria. ISRN Parasitol. 2013; 2013: 960168.
328063	Nigeria	Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, Cousens S, Abiose A, Remme JH. Impact of Long-term Treatment of Onchocerciasis with Ivermectin in Kaduna State, Nigeria: First Evidence of the Potential for Elimination in the Operational Area of the African Programme for Onchocerciasis Control. Parasites Vectors. 2012; 5(1).
328083	Nigeria	Uttah E. Onchocerciasis in the upper imo river basin, Nigeria: prevalence and comparative study of waist and shoulder snips from mesoendemic communities. Iran J Parasitol. 2010; 5(2): 33-41.
328089	Nigeria	Sam-Wobo SO, Adeleke MA, Jayeola OA, Adeyi AO, Oluwole AS, Ikenga M, Lawniye F, Gazama J, Kagni A, Kosoko TO, Agbeyangi O, Bankole S, Toé L, Mafiana CF, Yameogo L. Epidemiological evaluation of onchocerciasis along Ogun River System, southwest Nigeria. J Vector Borne Dis. 2012; 49(2): 101-4.
332571	Nigeria	Akogun OB, Akoh JI, Hellandendu H. Non-ocular clinical onchocerciasis in relation to skin microfilaria in the Taraba River Valley, Nigeria. J Hyg Epidemiol Microbiol Immunol. 1992; 36(4): 368–83.
332576	Nigeria	Anosike JC, Onwuliri CO. Studies on filariasis in Bauchi State, Nigeria. 1. Endemicity of human onchocerciasis in Ningi Local Government Area. Ann Trop Med Parasitol. 1995; 89(1): 31–8.
332594	Nigeria	Nwaorgu OC, Ohaegbula A, Onweluzo IE, Alo ET, Nweke LN, Agu ML, Emeh E. Results of a large scale onchocercosis survey in Enugu State, Nigeria. J Helminthol. 1994; 68(2): 155–9.
332703	Nigeria	Emukah E, Nimzing J, Ezeabikwa M, Obiezu J, Okpala N, Miri E, Katabarwa M, Hopkins D, Richards F. Impact assessment of repeated annual ivermectin on ocular

NID	Geographies	Citation
		and clinical onchocerciasis 14 years of annual mass drug administration in eight sentinel villages, southeast Nigeria 2008. Am J Trop Med Hyg. 2010; 83(Suppl 5): 22.
332707	Nigeria	Olofintoye LK, Adewole SO, Erinle FB, Ajayi AI. Prevalence of Onchoceriasis Syndrome in Ise-Orun Local Government Area of Ekiti State, Nigeria. Pak J Sci Ind Res. 2005; 48(6): 412-6.
332712	Nigeria	Oyibo WA, Fagbenro-Beyioku AF. Reduced prevalence of onchocerciasis following mass treatment with ivermectin. East Afr Med J. 1997; 74(5): 326–30.
332714	Nigeria	Rebecca SN, Akinboye DO, Abdulazeez AA. Onchocerciasis and Plasmodiasis: Concurrent Infection in Garaha-Dutse Community, Adamawa State Nigeria. Biomed Res. 2008; 19(2): 107-11.
332717	Nigeria	Abanobi OC, Anosike JC. Control of onchocerciasis in Nzerem-Ikpem, Nigeria: baseline prevalence and mass distribution of ivermectin. Public Health. 2000; 114(5): 402–6.
332719	Nigeria	Akinboye DO, Okwong E, Ajiteru N, Fawole O, Agbolade O, Ayinde OO, Amosu AM, Atulomah NOS, Oduola O, Owodunni BM, Rebecca SN, Falade M. Onchocerciasis Among Inhabitants of Ibarapa Local Government Community of Oyo State, Nigeria. Biomed Res. 2010; 21(2): 174-8.
332723	Nigeria	Akogun OB, Musa-Hong H, Hellandendu H. Onchocerciasis in Taraba State, Nigeria: intensity, rate of infection and associated symptoms in 14 communities of Bali district. Appl Parasitol. 1994; 35(2): 125–32.
332725	Nigeria	Akogun OB, Akoh JI, Okolo A. Comparison of two sample survey methods for hyperendemic onchocerciasis and a new focus in Dakka, Nigeria. Rev Biol Trop. 1997; 45(2): 871–6.
332728	Nigeria	Akogun OB. Onchocerciasis in Taraba State, Nigeria: clinical-epidemiological study of at-risk males in Bakundi District. Zentralbl Bakteriol. 1999; 289(3): 371–9.
332730	Nigeria	Nmorsi OPG, Oladokun I a. A, Egwunyenga OA, Oseha E. Eye lesions and onchocerciasis in a rural farm settlement in Delta state, Nigeria. Southeast Asian J Trop Med Public Health. 2002; 33(1): 28–32.
332732	Nigeria	Opara KN, Fagbemi BO, Atting IA, Oyene UE, Okenu DMN. Status of forest onchocerciasis in the Lower Cross River Basin, Nigeria: change in clinical and parasitological indices after 6 years of ivermectin intervention. Public Health. 2007; 121(3): 202–7.
332734	Nigeria	Umeh RE, Chijioke CP, Okonkwo PO. Eye disease in an onchocerciasis-endemic area of the forest-savanna mosaic region of Nigeria. Bull World Health Organ. 1996; 74(1): 95–100.
332736	Nigeria	Umeh RE. The causes and profile of visual loss in an onchocerciasis-endemic forest-savanna zone in Nigeria. Ophthalmic Epidemiol. 1999; 6(4): 303–15.
332899	Nigeria	Anosike JC, Celestine NA, Onwuliri OE, Onwuliri VA. The prevalence, intensity and clinical manifestations of Onchocerca volvulus infection in Toro local government area of Bauchi State, Nigeria. Int J Hyg Environ Health. 2001; 203(5–6): 459–64.
332905	Nigeria	Nwosu SN. Low vision in persons aged 50 and above in the onchocercal endemic communities of Anambra State, Nigeria. West Afr J Med. 2000; 19(3): 216–9.

NID	Geographies	Citation
332907	Nigeria	Abanobi OC. Cross-validation of the rapid epidemiological mapping of onchocerciasis endemicity in Anambra state, Nigeria. Ann Trop Med Parasitol. 1999; 93(7): 721–6.
327879	Senegal	Wilson NO, Badara Ly A, Cama VA, Cantey PT, Cohn D, Diawara L, Direny A, Fall M, Feeser KR, Fox LM, Kabore A, Seck AF, Sy N, Ndiaye D, Dubray C. Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin. PLoS Negl Trop Dis. 2016; 10(12): e0005198.
136415	Sierra Leone	Gbakima AA, Sahr F. Filariasis in the Kaiyamba Chiefdom, Moyamba District Sierra Leone: an epidemiological and clinical study. Public Health. 1996; 110(3): 169-74.
155864	Sierra Leone	Gbakima AA. Inland valley swamp rice development: malaria, schistosomiasis, onchocerciasis in south central Sierra Leone. Public Health. 1994; 108(2): 149-57.
334430	Sierra Leone	Gbakima AA, Barbe RF. Onchocerca Volvulus infection in Sierra Leone: relation between prevalence, intensity of infection, and ocular problems in a "forest" region. Acta Leiden. 1992; 60(2): 47–59.
334432	Sierra Leone	Gbakima AA. Integrated control of Onchocerca volvulus infection in a hyperendemic zone in Sierra Leone. East Afr Med J. 1996; 73(3): 159–63.
327874	Sudan	Higazi TB, Zarroug IMA, Mohamed HA, Elmubark WA, Deran TCM, Aziz N, Katabarwa M, Hassan HK, Unnasch TR, Mackenzie CD, Richards F, Hashim K. Interruption of Onchocerca volvulus transmission in the Abu Hamed focus, Sudan. Am J Trop Med Hyg. 2013; 89(1): 51–7.
327986	Tanzania	Mweya CN, Kalinga AK, Kabula B, Malley KD, Ruhiso MH, Maegga BTA. Onchocerciasis situation in the Tukuyu focus of southwest Tanzania after ten years of ivermectin mass treatment. Tanzan Health Res Bull. 2007; 9(3): 174-9.
332901	Tanzania	Makunde WH, Salum FM, Massaga JJ, Alilio MS. Clinical and parasitological aspects of itching caused by onchocerciasis in Morogoro, Tanzania. Ann Trop Med Parasitol. 2000; 94(8): 793–9.
327919	Togo	Golden A, Faulx D, Kalnoky M, Stevens E, Yokobe L, Peck R, Karabou P, Banla M, Rao R, Adade K, Gantin RG, Komlan K, Soboslay PT, de Los Santos T, Domingo GJ. Analysis of age-dependent trends in Ov16 IgG4 seroprevalence to onchocerciasis. Parasites Vectors. 2016; 9(1): 338.
338602	Togo	Dogba PK, Komi BT. [The evaluation of endemic onchocerciasis in the Amou prefecture (Togo)]. Bull Soc Pathol Exot. 1994; 87(2): 110–1.
327978	Uganda	Katabarwa M, Lakwo T, Habomugisha P, Agunyo S, Byamukama E, Oguttu D, Ndyomugyenyi R, Tukesiga E, Ochieng GO, Abwaimo F, Onapa A, Lwamafa DWK, Walsh F, Unnasch TR, Richards FO. Transmission of Onchocerca volvulus by Simulium neavei in Mount Elgon focus of Eastern Uganda has been interrupted. Am J Trop Med Hyg. 2014; 90(6): 1159-66.
328051	Uganda	Katabarwa MN, Lakwo T, Habomugisha P, Agunyo S, Byamukama E, Oguttu D, Tukesiga E, Unoba D, Dramuke P, Onapa A, Tukahebwa EM, Lwamafa D, Walsh F, Unnasch TR. Transmission of Onchocerca volvulus continues in Nyagak-Bondo focus of northwestern Uganda after 18 years of a single dose of annual treatment with ivermectin. Am J Trop Med Hyg. 2013; 89(2): 293-300.
332836	Uganda	Kipp W, Bamhuhiiga J, Rubaale T, Kabagambe G. Adverse reactions to the ivermectin treatment of onchocerciasis patients: does infection with the human immunodeficiency virus play a role?. Ann Trop Med Parasitol. 2005; 99(4): 395-402.

NID	Geographies	Citation
332845	Uganda	Ndyomugyenyi R, Tukesiga E, Büttner DW, Garms R. The impact of ivermectin treatment alone and when in parallel with Simulium neavei elimination on onchocerciasis in Uganda. Trop Med Int Health. 2004; 9(8): 882-6.
333505	Uganda	Fischer P, Kipp W, Bamuhiga J, Binta-Kahwa J, Kiefer A, Büttner DW. Parasitological and clinical characterization of Simulium neavei-transmitted onchocerciasis in western Uganda. Trop Med Parasitol. 1993; 44(4): 311–21.
333506	Uganda	Fischer P, Kipp W, Kabwa P, Buttner DW. Onchocerciasis and human immunodeficiency virus in western Uganda: prevalences and treatment with ivermectin. Am J Trop Med Hyg. 1995; 53(2): 171–8.
334413	Uganda	Katabarwa M, Onapa AW, Nakileza B. Rapid epidemiological mapping of onchocerciasis in areas of Uganda where Simulium neavei sl is the vector. East Afr Med J. 1999; 76(8): 440–6.
334415	Uganda	Katabarwa MN, Walsh F, Habomugisha P, Lakwo TL, Agunyo S, Oguttu DW, Unnasch TR, Unoba D, Byamukama E, Tukesiga E, Ndyomugyenyi R, Richards FO. Transmission of Onchocerciasis in Wadelai Focus of Northwestern Uganda Has Been Interrupted and the Disease Eliminated [Internet]. J Parasitol Res. 2012.
334417	Uganda	Katabarwa M. Has interruption of Simulium neavei s.s transmitted onchocerciasis been attained in the Kashoya-Kitomi focus?. 2010.
334419	Uganda	Kipp W, Bamuhiga JT, Kwered EM. Onchocerciasis prevalence in previously known foci in western Uganda: results from a preliminary survey in Kabarole district. Trop Med Parasitol. 1992; 43(2): 80–2.
334420	Uganda	Lakwo TL, Garms R, Rubaale T, Katabarwa M, Walsh F, Habomugisha P, Oguttu D, Unnasch T, Namanya H, Tukesiga E, Katamanywa J, Bamuhiiga J, Byamukama E, Agunyo S, Richards F. The disappearance of onchocerciasis from the Itwara focus, western Uganda after elimination of the vector Simulium neavei and 19 years of annual ivermectin treatments. Acta Trop. 2013; 126(3): 218–21.
334422	Uganda	Okello DO, Ovuga EB, Ogwal-Okeng JW. Dermatological problems of onchocerciasis in Nebbi District, Uganda. East Afr Med J. 1995; 72(5): 295–8.

204
205
206

Supplementary Figure 3. Africa and Yemen data coverage maps.

Locations of the unique point and polygon data used in modelling, grouped by years: 1988–1999, 2000–2004, 2005–2009, and 2010–2018. Hatched countries were not included in the MBG modelling region. Data that were able to be matched to point coordinates are represented by red dots and data that represented a larger area are represented by blue polygons.

3.5 APOC survey year matching

The African Programme for Onchocerciasis Control (APOC),(3) which operated from 1995 to 2015, relied on Rapid Epidemiological Mapping of Onchocerciasis (REMO) to map baseline onchocerciasis prevalence and endemicity in 19 onchocerciasis-endemic African countries outside the Onchocerciasis Control Programme (OCP) focal region (APOC was later expanded to additional countries). REMO(4,5) mapping, involving village-level surveys of nodule (onchocercoma) prevalence among adult males, was completed for 12 APOC countries by 2001.(6) We obtained these pre-2001 nodule mapping data, when available, from the ESPEN data portal, although detailed information on survey years were lacking for many (N = 4409) of these datapoints. So that these essential baseline mapping surveys could inform our spatiotemporal model of onchocerciasis prevalence, we investigated the pre-2001 REMO mapping surveys in APOC countries and attempted to narrow the possible range of survey years for these data. As widespread use of REMO by APOC began in 1996,(6) and these data were indicated by the ESPEN database as representing pre-2001 surveys, we considered 1996 and 2000 as the initial lower and upper bounds for survey years. We next identified survey locations for which the first year of onchocerciasis MDA (mass drug administration) occurred prior to 2001 (see section 4.2 below) and assumed that baseline mapping occurred at that location no later than the preceding year, treating that year as the new upper bound. Finally, we examined the available literature on pre-2001 APOC REMO surveys, by country, to further narrow the possible range of survey years. Our decisions around survey year estimates are summarised in Supplementary Table 4. For each datapoint, we specified the final survey year as the median of the lower and upper year bounds (rounding down), considering this approach to balance the potential conflicting biases from incorrect survey years on the temporal trends in the MBG model and the association with environmental and sociodemographic covariates in child models.

Survey year data were also missing for some Phase 1a and 1b monitoring and evaluation surveys in the APOC data retrieved from ESPEN. We identified survey years for most of these data by matching them to the locations, sample sizes, cases, and number of villages reported by Tekle et al.,(7) supplemented with additional sources(8,9) for some countries. We identified survey years for a total of 1001 observations. Survey years could not be reliably identified for some Phase 1a and 1b data, specifically Phase 1a data for Kasai Occidental (Democratic Republic of the Congo, DRC), Phase 1a and 1b data for Bioko Island (Equatorial Guinea), Phase 1a data for Kogi (Nigeria), and some Phase 1b data for Uganda; these data were excluded from our analysis. We assumed sample age ranges of 5–99 years of age for Phase 1a and 1b data(7) unless the ESPEN dataset indicated otherwise.

Supplementary Table 4. APOC REMO survey year investigations. CDTI: Community-directed treatment with ivermectin.

Country	Data Rows	Notes	Survey Year Strategy
Central African Republic	875	CDTI began in some areas in 1993, following REMO surveys.(10)	Use 1992 (one year prior to CDTI initiation) as lower bound.
Cameroon	389	Early proof-of-concept tests of the REMO methodology were performed in Cameroon in 1993.(4)	Assume 1993 as lower bound.
Democratic Republic of Congo	684	REMO began in 1997 in certain foci and continued until 2008;(11) CDTI areas were established in 1999 based on REMO.(12)	REMO appears to have been undertaken between 1997 and 1999 (although Bof(11) noted that it continued through 2008; ESPEN data include surveys beyond 2001). Assume 1997 as lower bound for pre-2001 DRC nodule surveys.
Republic of Congo	290	No information found except an MDA start year of 2001 for a small subset of these locations.	Assume 1996 as lower bound.
Ethiopia	283	Country-wide REMO was performed in Ethiopia in 1997 and 2001.(13)	Use 1997 as survey year for pre-2001 data.
Kenya	93	No information found.	Assume 1996 as lower bound for pre-2001 data.

Country	Data Rows	Notes	Survey Year Strategy
Nigeria	576	REMO was reported in 1995 to have been used for nationwide mapping;(3) another source indicated that REMO was carried out in Nigeria between 1994 and 1996.(14)	Assume 1994 and 1995 as lower and upper bounds of survey years for pre-2001 data.
Rwanda	90	Nationwide REMO was performed in 1999.(15)	Use 1999 as survey year for pre-2001 data.
Sudan	2	No information found.	Assume 1996 as lower bound.
South Sudan	110	REMO was performed between 1995 and 2002.(16)	Assume 1995 as lower bound.
Chad	481	REMO performed prior to 1999.(17)	Assume 1996 as lower bound, and 1998 as upper bound for surveys otherwise lacking upper bound estimates based on MDA.
Tanzania	142	Years of initiation of CDTI in Tanzania ranged from 1995 to 2004.(7)	Use 1994 as lower bound estimate.
Uganda	394	Nationwide REMO conducted between 1993 and 1997.(18)	Use 1993 and 1997 as lower and upper bounds, respectively.

244

4.0 Supplementary covariates

4.1 Pre-existing covariates considered for analysis

A variety of environmental and sociodemographic variables were used to predict all-age onchocerciasis prevalence. Where available, the finest spatiotemporal resolution of gridded datasets was used. Geospatial covariate rasters were resampled to ~ 5 km in GeoTiff format, for consistent modelling. Where data coverage was inconsistent between our standard mask and the input data, either a local average or nearest neighbour method (depending on data type) was used to fill spatial data gaps. Data from the nearest year available were used if covariate coverage did not include all model years. Supplementary Table 5 contains a full list of covariates considered in our analysis.

4.2 Creation of MDA covariate

Data used in the creation of the onchocerciasis MDA covariate were downloaded from the ESPEN Portal in April 2019.(19) The ESPEN data included the MDA start year and cumulative number of MDA rounds for each IU. ArcGIS software was then used to join the MDA data to the NTD (Neglected Tropical Disease) Implementation Unit Shapefile maintained by the Task Force for Global Health. A custom polygon was created for Sudan by referencing annual reports from The Carter Center. The MDA covariate value was set calculated as the cumulative number of rounds (defined as total number of rounds implemented) for the IU, and then converted to a raster for use in geospatial analysis. Data for lymphatic filariasis MDA were obtained from WHO(20) for the years during which LF (lymphatic filariasis) MDA was conducted, by IU, and joined onto the IU shapefile maintained by ESPEN. So that the effects of MDA for onchocerciasis and lymphatic filariasis were not double-counted in locations where both were indicated, a composite MDA covariate was produced which indicated the cumulative number of years for which either onchocerciasis or lymphatic filariasis MDA was indicated. This composite covariate was used in modelling.

4.3 Covariate reduction

High collinearity among covariates may lead to unstable model coefficients and unreliable predictions.[37] To reduce this problem, we derived a reduced covariate set using analysis of variance inflation factors (VIF).(22) Starting with the full list of covariates, we iteratively removed covariates with the highest VIF values until all remaining covariates had a VIF below 3.0. The reduced covariate set was used in fitting the MBG model and for spatiotemporal predictions. Supplementary Table 5 indicates the covariates that were retained in the final model, with representative plots provided for each covariate in Supplementary Figure 4. All variables were matched to the

20

274   year of reported prevalence data, without any temporal lags (eg, temperature values for the year 2000 were joined to
275   prevalence data for the year 2000).

276 **Supplementary Table 5. Covariates considered or retained for modelling, 1988–2018.**

277 All covariates considered for inclusion as predictors of onchocerciasis prevalence. Short names are provided for reference in later figures and tables. Covariates
278 retained after VIF analysis are indicated with a (+).
279

Covariate	Short Name	Retained in Final Model	Years Available	Source	Reference
Aridity	crutsard	-	1988–2018	Climatic Research Unit Time-Series (CRUTS)	Harris, I., Osborn, T.J., Jones, P. et al. Version 4 of the CRU TS monthly high-resolution gridded multivariate climate dataset. Sci Data 7, 109 (2020). https://doi.org/10.1038/s41597-020-0453-3
					University of East Anglia. Climatic Research Unit TS v. 4.04 dataset. Available at: https://crudata.uea.ac.uk/cru/data/hrg/
Average daily mean temperature	crutstmp	+	1988–2018	CRUTS	Harris, I., Osborn, T.J., Jones, P. et al. Version 4 of the CRU TS monthly high-resolution gridded multivariate climate dataset. Sci Data 7, 109 (2020). https://doi.org/10.1038/s41597-020-0453-3
					University of East Anglia. Climatic Research Unit TS v. 4.04 dataset. Available at: https://crudata.uea.ac.uk/cru/data/hrg/
Average daily minimum temperature	crutstmn	-	1988–2018	CRUTS	Harris, I., Osborn, T.J., Jones, P. et al. Version 4 of the CRU TS monthly high-resolution gridded multivariate climate dataset. Sci Data 7, 109 (2020). https://doi.org/10.1038/s41597-020-0453-3
					University of East Anglia. Climatic Research Unit TS v. 4.04 dataset. Available at: https://crudata.uea.ac.uk/cru/data/hrg/
Average daily maximum temperature	crutstmx	-	1988–2018	CRUTS	Harris, I., Osborn, T.J., Jones, P. et al. Version 4 of the CRU TS monthly high-resolution gridded multivariate climate dataset. Sci Data 7, 109 (2020). https://doi.org/10.1038/s41597-020-0453-3
					University of East Anglia. Climatic Research Unit TS v. 4.04 dataset. Available at: https://crudata.uea.ac.uk/cru/data/hrg/
Diurnal temperature range	crutsdtr	+	1988–2018	CRUTS	Harris, I., Osborn, T.J., Jones, P. et al. Version 4 of the CRU TS monthly high-resolution gridded multivariate climate dataset. Sci Data 7, 109 (2020). https://doi.org/10.1038/s41597-020-0453-3
					University of East Anglia. Climatic Research Unit TS v. 4.04 dataset. Available at: https://crudata.uea.ac.uk/cru/data/hrg/

Covariate	Short Name	Retained in Final Model	Years Available	Source	Reference
Vapor pressure	crutsvap	-	1988–2018	CRUTS	Harris, I., Osborn, T.J., Jones, P. et al. Version 4 of the CRU TS monthly high-resolution gridded multivariate climate dataset. Sci Data 7, 109 (2020). https://doi.org/10.1038/s41597-020-0453-3
					University of East Anglia. Climatic Research Unit TS v. 4.04 dataset. Available at: https://crudata.uea.ac.uk/cru/data/hrg/
Wet day frequency	crutswet	+	1988–2018	CRUTS	Harris, I., Osborn, T.J., Jones, P. et al. Version 4 of the CRU TS monthly high-resolution gridded multivariate climate dataset. Sci Data 7, 109 (2020). https://doi.org/10.1038/s41597-020-0453-3
					University of East Anglia. Climatic Research Unit TS v. 4.04 dataset. Available at: https://crudata.uea.ac.uk/cru/data/hrg/
Distance to rivers >25 m wide	distrivers25m	+	Synoptic	Natural Earth Data (derived)	Andreadis KM, Schumann GJ-P, Pavelsky T. A simple global river bankfull width and depth database. Water Resources Research. 2013;49(10):7164–8.
River width (largest river within 5x5 km cell)	river_size	+	Synoptic	Natural Earth Data (derived)	Andreadis KM, Schumann GJ-P, Pavelsky T. A simple global river bankfull width and depth database. Water Resources Research. 2013;49(10):7164–8.
Elevation	elevation	-	Synoptic	NOAA/NCEI	Young, A. H., K. R. Knapp, A. Inamdar, W. B. Rossow, and W. Hankins, 2017: "The International Satellite Cloud Climatology Project, H-Series Climate Data Record Product", Earth System Science Data, in preparation.
Enhanced Vegetation Index (EVI)	evi_v6	+	2000–2018	MODIS	Huete, A., Justice, C. & van Leeuwen, W. MODIS vegetation index (MOD 13) algorithm theoretical basis document. (1999).
					USGS & NASA. Vegetation indices 16-Day L3 global 500m MOD13A1 dataset. Available at: https://lpdaac.usgs.gov/dataset_discovery/modis/m odis_products_table/mod13a1. (Accessed: 25th July 2017)
					Weiss, D. J. et al. An effective approach for gapfilling continental scale remotely sensed timeseries. Isprs J. Photogramm. Remote Sens. 98, 106–118 (2014).
					C. Schaaf, Z. Wang. (2015). MCD43A1 MODIS/Terra+Aqua BRDF/Albedo Model Parameters Daily L3 Global - 500m V006. NASA EOSDIS Land Processes DAAC. http://doi.org/10.5067/MODIS/MCD43A1.006
Population	worldpop	+	1988–2018	WorldPop	Lloyd, C. T., Sorichetta, A. & Tatem, A. J. High resolution global gridded data for use in population studies. Sci. Data 4, sdata20171 (2017).
					World Pop. Get data. Available at: http://www.worldpop.org.uk/data/get_data/. (Accessed: 25th July 2017)

Covariate	Short Name	Retained in Final Model	Years Available	Source	Reference
Growing season length	growingseason	-	Synoptic	FAO	FAO. GAEZ - Global Agro-Ecological Zones data portal. Available at: http://www.fao.org/nr/gaez/about-data-portal/en/. (Accessed: 25th July 2017) FAO. GAEZ - Global Agro-Ecological Zones users guide. (2012).
Tassled cap brightness	tcb_v6	+	2000–2017	MODIS	USGS & NASA. Nadir BRDF- Adjusted Reflectance Reflectance 16-Day L3 Global 1km dataset. Available at: https://lpdaac.usgs.gov/dataset_discovery/modis/modis_products_table/mcd43b4. (Accessed: 25th July 2017) Strahler, A. H. & Muller, J.-P. MODIS BRDF/Albedo product: algorithm theoretical basis document version 5.0. (1999). Weiss, D. J. et al. An effective approach for gapfilling continental scale remotely sensed timeseries. Isprs J. Photogramm. Remote Sens. 98, 106–118 (2014). C. Schaaf, Z. Wang. (2015). MCD43A1 MODIS/Terra+Aqua BRDF/Albedo Model Parameters Daily L3 Global - 500m V006. NASA EOSDIS Land Processes DAAC. http://doi.org/10.5067/MODIS/MCD43A1.006
Precipitation (Multi-source Weighted-Ensemble)	mswep	+	1988–2016	Princeton Climate Analytics	Beck, H.E., A.I.J.M. van Dijk, V. Levizzani, J. Schellekens, D.G. Miralles, B. Martens, A. de Roo: MSWEP: 3-hourly 0.25 global gridded precipitation (1979-2015) by merging gauge, satellite, and reanalysis data, Hydrology and Earth System Sciences, 21(1), 589-615, 2017.
Slope for land surfaces	slope	+	Synoptic	NOAA/NCEI	Young, A. H., K. R. Knapp, A. Inamdar, W. B. Rossow, and W. Hankins, 2017: "The International Satellite Cloud Climatology Project, H-Series Climate Data Record Product", Earth System Science Data, in preparation.
Soil: Saturated water content (200 cm depth)	sgawcts	-	Synoptic	SoilGrid	Hengl T, Mendesde Jesus J, MacMillan RA, Batjes NH, Heuvelink GBM, Ribeiro E, Samuel-Rosa A, Kempen B, Leenaars JGB, Walsh MG, Gonzalez MR. "SoilGrids1km — Global soil information based on automated mapping." PLOS ONE 9(8): e105992. 29 Aug 2014. doi:10.1371/journal.pone.0105992
Soil: Probability of bedrock exposure	sgbdrlog	+	Synoptic	SoilGrid	Hengl T, Mendesde Jesus J, MacMillan RA, Batjes NH, Heuvelink GBM, Ribeiro E, Samuel-Rosa A, Kempen B, Leenaars JGB, Walsh MG, Gonzalez MR. "SoilGrids1km — Global soil information based on automated mapping." PLOS ONE 9(8): e105992. 29 Aug 2014. doi:10.1371/journal.pone.0105992
Soil: Bulk density (200 cm depth)	sgbldfie	+	Synoptic	SoilGrid	Hengl T, Mendesde Jesus J, MacMillan RA, Batjes NH, Heuvelink GBM, Ribeiro E, Samuel-Rosa A, Kempen B, Leenaars JGB, Walsh MG, Gonzalez MR. "SoilGrids1km — Global soil information based on automated mapping." PLOS ONE 9(8): e105992. 29 Aug 2014. doi:10.1371/journal.pone.0105992
Soil: Clay content mass fraction (200 cm depth)	sgclyppt	+	Synoptic	SoilGrid	Hengl T, Mendesde Jesus J, MacMillan RA, Batjes NH, Heuvelink GBM, Ribeiro E, Samuel-Rosa A, Kempen B, Leenaars JGB, Walsh MG, Gonzalez MR. "SoilGrids1km — Global soil

24

Covariate	Short Name	Retained in Final Model	Years Available	Source	Reference
					information based on automated mapping." *PLOS ONE* 9(8): e105992. 29 Aug 2014. doi:10.1371/journal.pone.0105992
Soil: Coarse fragments (200 cm depth)	sgcrfvol	+	Synoptic	SoilGrid	Hengl T, Mendesde Jesus J, MacMillan RA, Batjes NH, Heuvelink GBM, Ribeiro E, Samuel-Rosa A, Kempen B, Leenaars JGB, Walsh MG, Gonzalez MR. "SoilGrids1km — Global soil information based on automated mapping." *PLOS ONE* 9(8): e105992. 29 Aug 2014. doi:10.1371/journal.pone.0105992
Cumulative years of mass drug administration (MDA) for lymphatic filariasis or onchocerciasis	allmda	+	1988–2018	WHO (rasters produced in current study)	WHO. Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN). https://www.espen.org/ (accessed May 20, 2020). WHO. Global Programme to Eliminate Lymphatic Filariasis. http://www.who.int/lymphatic_filariasis/elimination- programme/en/ (accessed May 29, 2019).

280

Supplementary Figure 4. Africa and Yemen covariate values.

15 environmental or sociodemographic variables were used as inputs for the modelling process for Africa and Yemen (river size is not shown in this figure). Time-varying covariates are presented here for the year 2015. Please refer to Supplementary Table 5 for the corresponding citations for each covariate.

5.0 Supplementary methods
5.1 Age and diagnostic crosswalks

Surveys of onchocerciasis prevalence have varied in both their sampled age ranges and in the diagnostic tests they utilised. For example, epidemiological surveys during the OCP program relied on skin snip (microfiladermia) examinations of individuals aged 5 years or older,[23,24] while APOC relied on the REMO (Rapid Epidemiological Mapping of Onchocerciasis)[5,6,25,26] methodology to identify endemic areas requiring MDA, employing nodule palpation in adults. To harmonise these data sources, we adjusted survey data to represent all-age microfiladermia

294 prevalence by developing and applying an age and diagnostic crosswalk model that simultaneously accounts for
295 typical age-dependent trends in prevalence and differential detection sensitivity between skin snip examination and
296 nodule palpation. We did not crosswalk results from antibody (eg, Ov16) surveys as these data were not used in
297 fitting the MBG model.
298
299 We identified published within-study comparisons reporting results from skin snip biopsies (microfiladermia),
300 nodule (onchocercoma) palpation, or both, for more than one age group in a given study population. Study cohorts
301 with zero reported cases were excluded from the crosswalk training dataset because they do not contribute
302 information with which to derive age trends in endemic settings. Studies were eligible for inclusion in the crosswalk
303 training dataset if they reported data from a country in our MBG modelling region; all eligible studies reported data
304 from surveys conducted in our geospatial modelling timeframe (1988–2018). We identified 133 unique survey
305 populations from 36 studies reporting skin snip prevalence in multiple age groups, and 126 unique survey
306 populations from 22 studies reporting nodule prevalence in multiple age groups; among these surveys, a total of 100
307 unique survey populations from 19 studies reported both skin snip and nodule prevalence from the same study
308 populations and age groups. Supplementary Table 6 summarises these sources.

309 **Supplementary Table 6. Data used in estimation of age and diagnostic crosswalk.**

310 Note that studies may have reported data for additional diagnostic tests that were not used in crosswalk model
311 fitting.

Countries	Survey Years	Diagnostic Data
Benin(27)	1991	skin snip, nodule
Cameroon(28)	1992	skin snip
Cameroon(29)	1992	skin snip, nodule
Cameroon(30)	1996, 2005, 2006, 2011	skin snip, nodule
Cameroon(31)	2000	nodule
Cameroon(32)	2008	skin snip, nodule
Cameroon(33)	2009	skin snip, nodule
Cameroon(34)	2009	skin snip, nodule
Cameroon(35)	2012	skin snip, nodule
Cameroon(36)	2015	skin snip, nodule
Cameroon(37)	2015	skin snip, nodule
Cameroon(38)	2015	skin snip, nodule
Cameroon, Uganda(39)	1993 (Uganda), 1996 (Cameroon), 2005 (both countries)	skin snip, nodule
Central African Republic(40)	1990, 1995	skin snip
Ethiopia(41)	1994	skin snip, nodule
Ethiopia(42)	1997	skin snip

Ethiopia(43)	2005	skin snip
Ethiopia(44)	2006	skin snip
Ethiopia(45)	2012	skin snip
Gabon(46)	2004	nodule
Nigeria(47)	1992	skin snip
Nigeria(48)	1994	skin snip, nodule
Nigeria(49)	1994	skin snip
Nigeria(50)	1997	skin snip
Nigeria(51)	2000	skin snip, nodule
Nigeria(52)	2005	skin snip
Nigeria(53)	2007	skin snip
Nigeria(54)	2008	skin snip, nodule
Nigeria(55)	2008	skin snip
Nigeria(56)	2008	skin snip, nodule
Nigeria(57)	2009	skin snip
Nigeria(58)	2009	skin snip, nodule
Nigeria(59)	2010	nodule
Sierra Leone (60)	2010	skin snip
Togo(61)	1992	skin snip
Togo(62)	2014	skin snip
Togo(63)	2015	skin snip
Uganda(64)	1993	skin snip, nodule
Uganda(65)	2012	skin snip, nodule

312
313 We first retrieved population estimates by single age-year from the Global Burden of Disease (GBD)(66) for the
314 country and year of each survey in the crosswalk training set. We assumed that the age distribution ($P(A)$, or
315 probability of age A) within a survey sample matched that in the country and year of the survey, and estimated
316 prevalence-by-age models ($P(D|A)$, or the probability of disease, D, at age A) from birth through age 94 years, the
317 maximum individual age-year modelled by GBD. We used the GBD age distributions to estimate the likelihood of
318 observing the reported number of cases in each surveyed age bin, given a logistic (binomial) regression model of the
319 average prevalence-by-age relationship across surveys:
320
321 $$\text{logit}\big(P(D|A)\big) = \beta_0 + I_{ss}f_{ss}(A) + I_{nod}f_{nod}(A) + \alpha_i + I_{ss}\beta_{ss}$$
322
323 Onchocerciasis prevalence at a given age ($P(D|A)$) was modelled in logit space as a linear combination of an
324 intercept, β_0, which was set at logit(0.00001) to drive prevalence at birth toward zero; basis splines (fda R
325 package(67)) on age, $f(A)$, to accommodate non-linear age trends; α_i, cohort-level fixed effects (indicator variables

28

326   identifying study cohorts in the training dataset) to account for differences in study populations and survey designs;
327   and a fixed diagnostic effect for skin snip surveys, β_{ss}, to model overall differences between skin snip and nodule
328   surveys. Diagnostic indicator variables, I_{ss} and I_{nod}, were set to 1 for skin snip and nodule observations,
329   respectively, and set to 0 otherwise, to select the appropriate age and diagnostic effects for a given survey. Study
330   cohort effects were assumed to be shared across diagnostic tests. The likelihood function was evaluated as the sum,
331   across studies (i) and age bins ($A1 \leq A < A2$), of the binomial likelihood of observing the reported numbers of
332   cases given the reported sample sizes, age ranges, and diagnostic tests, using population-weighted mean prevalence
333   values evaluated at the midpoints of each age year.
334
335   Spline knot placements were identified by spacing four internal knots evenly by quantile in the training data,
336   determined separately for skin snip and nodule surveys, with additional knots placed at ages 3, 6, and 65 to help
337   stabilise model behaviour in early childhood and older adulthood. Starting values for all spline, cohort and
338   diagnostic coefficients were randomly drawn from uniform distributions in the interval [–5, 5]. Models were
339   estimated with maximum likelihood optimisation using the box constraint quasi-Newton algorithm[66] (without
340   constraints) in the optim function (R stats package(69)).
341
342   Prior to running the MBG model, all survey data that derived from a restricted age range (ie, anything other than 0–
343   94 years), or that represented nodule prevalence, were adjusted using the fitted crosswalk model. For each individual
344   survey population, the crosswalk model was refit via maximum likelihood to the prevalence data for that survey,
345   with all coefficients other than the cohort-level effect fixed, α_i, fixed to their estimates from the full crosswalk
346   model. This newly estimated value of α_i was then re-inserted into the crosswalk model with the other coefficients
347   fixed, to calculate all-age skin snip prevalence for that survey sample. Crosswalked estimates were then used as the
348   outcome measure in the MBG model.
349
350   Surveys that reported prevalence of 0% or 100% were particularly difficult to interpret for crosswalk purposes. A
351   report of 0% prevalence could reflect true absence of infection, insufficient diagnostic sensitivity, or sampling
352   variance in small samples, while a report of 100% prevalence masks any implicit linkage between prevalence and
353   the scale of infection intensity. While many of these concerns also apply to surveys reporting intermediate
354   prevalence, the particular uncertainty involved with surveys reporting 0% or 100% prevalence increases the risk of
355   inappropriate crosswalking, and for this reason we did not crosswalk such surveys.
356
357   Uncertainty in the crosswalk models was estimated using bootstrap analysis, with 100 replicates generated by
358   sampling, with replacement, an equal number of study cohorts as in the full crosswalk training dataset. Resampling
359   was conducted by cohort rather than age bin to better estimate variation among surveys. Spline knot locations and
360   model coefficients were estimated for each bootstrap replicate independently of other replicates and of the full
361   model. To visualise bootstrapped results for a given survey, cohort effects were calculated for each replicate using
362   maximum likelihood optimisation with all other coefficients fixed to the estimated values for the replicate.
363

364
365 **Supplementary Figure 5. Diagnostic and age crosswalk model.**

366 Outputs from the diagnostic and age crosswalk model. (**a**) Example prevalence-by-age curves fit to a study from
367 Benin(27) that reported both skin snip and nodule age-binned data and was included in the crosswalk model training
368 dataset. Estimates are shown for skin snip microfiladermia prevalence (solid black line) and nodule prevalence
369 (dotted green line); horizontal bars indicate the age-binned prevalence data reported by that study (solid gray: skin
370 snip; dotted green: nodule). (**b**) Bootstraped estimates of differences between microfiladermia (skin snip) and nodule
371 prevalence by age, in logit space. Each of 100 bootstrap samples is shown (faint grey line) along with the median
372 estimate (solid black line) and central 95% uncertainty interval (shaded area). Positive values indicate higher skin
373 snip prevalence than nodule prevalence.

30

374
375 In an example location with moderately high microfiladermia prevalence, our final crosswalk model (Supplementary
376 Figure 5) suggests a sharp increase in prevalence through childhood and adolescence, with a slower increase
377 between approximately ages 15 and 65 years. This general pattern is qualitatively consistent with the range of
378 onchocerciasis microfiladermia age trends reported by other studies,(70–72) although substantial site-specific
379 variation exists. The relationship between microfiladermia and nodule prevalence within onchocerciasis-endemic
380 communities was previously modelled by Coffeng et al.,(73) using pre-control data from a broad sampling of sites in
381 OCP and APOC regions. Their multivariate logistic regression model, relating nodule prevalence in adult males
382 (aged 20 years or older) to microfiladermia prevalence in individuals aged 5 years or older, did not explicitly model
383 changes in prevalence with age, but revealed higher prevalence estimates from skin snip biopsies than those from
384 nodule palpation surveys in the same communities. Our full crosswalk model and bootstrapped uncertainty estimates
385 (Supplementary Figure 5) are qualitatively consistent with their results, estimating that skin snip prevalence exceeds
386 nodule prevalence, on average, from adolescence until about age 50, with poorer resolution of this relationship in
387 children and older adults.
388
389 While crosswalking survey data that are based on differing diagnostics and age coverage enabled us to leverage a
390 more comprehensive geospatial dataset than is otherwise tractable, we identify several limitations to our crosswalk
391 approach. Our model assumes that, for a given diagnostic approach, changes in prevalence by age follow a
392 consistent pattern across locations, years, sexes, and programmatic contexts. However, actual and reported
393 microfiladermia and nodule prevalence patterns are influenced by local factors including ecological conditions;
394 infection intensity; vector identity, density, exposure, and control history; MDA coverage; variations in survey
395 sampling designs and in diagnostic specificity and sensitivity; and sex.(70,72–79) We have not modelled the age-
396 and diagnostic-specific effects of MDA on prevalence in the crosswalk models (although MDA is included as a
397 predictor during the MBG modelling stage). We were also limited by the variable reporting of age information
398 among data sources. Some surveys did not report age ranges, and for these surveys we assumed that their data
399 represented all-age prevalence, risking possible misclassification. The absence of individual-level data on
400 onchocerciasis prevalence also precluded full age-standardisation, as we could only assume that the survey sample
401 matched the age structure of the general population. Our crosswalks do not currently account for the sensitivity and
402 specificity of skin snip and nodule diagnostics, and crosswalk uncertainty is therefore likely to be underestimated.
403 We also do not currently have a computationally feasible method to propagate uncertainty from the crosswalk
404 models into the MBG models in a way that accounts for the inconsistent reporting of sampled age ranges among
405 studies.
406
407
408 **5.2 Polygon resampling**
409 Prevalence records are representative of either georeferenced point locations or polygonal areas (eg, as defined by
410 the borders of administrative or programmatic units). As our modelling framework relies on coordinate-referenced
411 data in order to fit the continuous spatial random fields, we converted areal data to a representative collection of
412 point data. This "polygon resampling" process, described previously for geostpatial modelling of under-5
413 mortality,(80) generates candidate locations based on the underlying population density of the resampled area,
414 implicitly assuming that surveys employed population-based designs, and is illustrated in Supplementary Figure 6
415 using Cameroon in 2015 as an example. For each polygonal observation in our dataset, 10 000 points were randomly
416 sampled from within the polygon, with weighting by the WorldPop total population raster. Candidate points were
417 clustered using k-means clustering, generating a set of final points with a density of 1 per 1000 grid cells, except for
418 small polygons, in which case density was iteratively increased by a factor of 10 until a minimum threshold of 10
419 points was achieved. Weights were assigned to each point proportionally to the number of candidate points that
420 entered into the k-means cluster. The points generated by this resampling process were assigned the prevalence of
421 onchocerciasis reported for the survey for that polygon. These sample weights were used in MBG model fitting
422 within INLA.

423
424
425   **Supplementary Figure 6. Polygon resampling.**

426   The process of polygon resampling is illustrated using reported onchocerciasis prevalence data for Cameroon in
427   2015. (**a**) National map of Cameroon, showing the inset area (red frame) that is featured in the remaining panels. (**b**)
428   Reported areal (irregular polygons) and point-level (circles) prevalence data. (**c**) Underlying population surface from
429   WorldPop (displayed on a $\log_{10}$ scale), with survey polygons overlayed. Polygons are resampled proportionally to 5
430   x 5 km population density. (**d**) Locations of the final datapoints for geospatial modelling, showing both those data
431   originally reported with coordinates and those derived by resampling the polygon data. The opacity of resampled
432   datapoints in (d) reflects their relative weights, which sum to 1.0 within an individual areal survey.

433 **5.3 Geostatistical model**
434 **5.3.1 Model geographies and time period**
435 Model-based geostatistical (MBG) methods were used to generate estimates of all-age onchocerciasis
436 microfiladermia prevalence for onchocerciasis-endemic countries of Africa, plus Yemen (listed in Supplementary
437 Table 2). A single model was fit to this geographical region. We did not model countries in the Western Hemisphere
438 that were formerly or are currently endemic for onchocerciasis, due to their highly localised onchocerciasis foci. We
439 were principally concerned with estimates for the time period 2000–2018, but fit the model using data from 1988–
440 2018 in order to leverage information from pre-2000 OCP and APOC surveys, and thereby improve "baseline" (ie,
441 year 2000) model estimates in countries covered by those programmes. Reporting of results in the main text focuses
442 on estimates for 2000–2018.
443
444 **5.3.2 Covariate coverage**
445 As with any regression model, the reliability of predictions from our model is affected by the overlap between
446 covariate values in training and prediction datasets. Predictions in regions with a range of covariate values that fall
447 outside the range of values in the training set may be prone to extrapolation errors. Supplementary Figure 7
448 illustrates the number of covariates whose mean values (averaged over 1988–2018) fall outside the central 95%
449 quantile interval of values in the training set, for each 5 x 5-km pixel. Child model predictions in areas with poor
450 covariate representation (ie, a large number of covariates with values outside the central interval) should be
451 considered with special caution. These areas include the Sahel and Sahara, as well as Yemen, Kenya, Somalia,
452 eastern Ethiopia, and southern Angola.
453
454 **5.3.3 Environmental suitability**
455 Cromwell et al. recently produced an environmental suitability model for onchocerciasis, using a boosted regression
456 tree (BRT) model trained with space- and time-referenced data on onchocerciasis occurrence. (81) In contrast to our
457 present MBG model, the Cromwell suitability model leveraged data from not only skin snip and nodule palpation
458 surveys, but also Ov16 serosurveys, onchocerciasis-derived eye or skin morbidity surveys, and other diagnostics.
459 The model was trained using an overlapping but non-identical set of environmental covariates as those used in the
460 present study, including climatic, topographic, hydrologic, vegetative, and urbanicity variables. Pseudo-absence
461 records were generated using background sampling. Importantly for our present purposes, this suitability model does
462 not incorporate the influence of programmatic interventions for onchocerciasis and does not use data on
463 onchocerciasis absence, providing a reflection of *O. volvulus* endemicity apart from temporal changes in infection
464 prevalence. The outputs of the BRT model represent a spatially explicit index from 0–1, reflecting environmental
465 suitability for onchocerciasis occurrence in a given 5 x 5-km cell. We incorporated mean predictions from this
466 suitability model, using covariate values for 2016 (Supplementary Figure 8), to improve the behaviour of our MBG
467 model in areas of poor prevalence data coverage, particularly in areas where covariates lie outside the range of
468 values in sampled locations and MBG predictions are therefore subject to extrapolation uncertainty.

Supplementary Figure 7. Number of covariates with values outside the central 95% interval of values at survey sites.

For each 5 x 5-km pixel, the number of covariates (out of a total of 16) whose average value lies outside the central 95% interval of values at observed survey sites is indicated. Localities with a large number of such covariates represent areas in which predictions are less reliable, due to potential extrapolation error.

Environmental Suitability Index
High
Low

478
479

Supplementary Figure 8. Onchocerciasis suitability model predictions (Cromwell et al., 2021) for 2016.

Mean environmental suitability for onchocerciasis, from a previous boosted regression tree (BRT) analysis (81) of onchocerciasis presence data, using covariate values for 2016.

5.3.4 Model description

We modelled *Onchocerca volvulus* infection prevalence using a spatially explicit Bayesian generalised linear mixed effects regression model in R-INLA:

$$Y_{i,t} \sim \text{Binomial}(p_{i,t}, N_{i,t})$$

$$\text{logit}(p_{i,t}) = \beta_0 + \beta X_{i,t} + \gamma_{c[i]} + U_i + Z_i + \epsilon_{i,t}$$

$$Z_i \sim GP(0, \Sigma_{space})$$

$$\epsilon_{i,t} \sim N(0, \sigma_{nug}^2)$$

495
496 The number of infected individuals ($Y_{i,t}$) among a sample ($N_{i,t}$) in location i and year t was modelled as a binomial
497 variable. This model specifies logit-transformed infection prevalence ($p_{i,t}$) as a linear combination of an intercept
498 for the modelling region (β_0); covariate fixed effects (coefficients, β, and values, $X_{i,t}$); country random effects
499 ($\gamma_{c[i]}$); a second-order random walk model on estimates of onchocerciasis environmental suitability (U_i); a spatially
500 correlated random field (Z_i); and an uncorrelated error term or nugget effect ($\epsilon_{i,t}$). The spatial random field (Z_i) was
501 modelled as a Gaussian process with mean 0 and a Matérn covariance function (Σ_{space}). Modelled outputs from the
502 BRT analysis of onchocerciasis environmental suitability (U_i), described in section 5.3.3, were modelled with a
503 second-order random walk, with values grouped into 25 bins by quantile. This random walk model accommodates
504 non-linearity in the relationship between suitability (based on presence-absence data) and the linear predictor. The
505 INLA (integrated nested Laplace approximation) model was fit using an "empirical Bayes" integration strategy,
506 which relies on mode values to approximate hyperparameter posterior distributions during estimation and enabled us
507 to achieve tractable model computation times.(82)
508
509 **5.3.5 Priors**
510 We specified minimally informative priors for INLA hyperparameters, as detailed in Supplementary Table 7. Priors
511 for the spatial hyperparameters τ and κ were derived automatically by R-INLA based on the finite elements mesh.
512 **Supplementary Table 7. INLA model priors.**

| Parameter	Description	Prior
β_0, β	Intercept, covariate fixed effects	$N(\mu = 0, \sigma^2 = 3^2)$
$\left(\frac{1}{\sigma^2_{country}}\right)$	Precision for country random effects ($\gamma_{c[i]}$, i.i.d.)	$gamma(a = 1, b = 0.00005)$
$\left(\frac{1}{\sigma^2_{nug}}\right)$	Precision for nugget effect ($\epsilon_{i,t}$, i.i.d)	$pc.\,prec(u = 0.5, \alpha = 0.05)$[1]
$\left(\frac{1}{\sigma^2_U}\right)$	Precision for suitability model (U_i, RW2 model)	$gamma(a = 1, b = 0.00005)$
σ_{SPDE}	Standard error for SPDE model	$pc(3.0, 0.05)$[2]
Range	Range for SPDE model	$pc(0.06171913, 0.05)$[3]

[1]PC prior for precision.
[2]PC prior for SPDE σ, indicating a 5% probability that σ is greater than 3.
[3]PC prior for SPDE range, indicating a 5% probability that range is less than 0.06161412 (5% of the maximum extent of the spatial mesh).

513
514 **5.3.6 Mesh construction**
515 We modelled continuous spatial random effects using stochastic partial differential equations (SPDE)
516 representations of Gaussian-Markov random field (GMRF) approximations of a spatially autocorrelated Gaussian
517 process, using triangular finite element meshes as implemented in the R-INLA R package.(83–85) Due to the large
518 geographical size of the model region, a spherical (S2) mesh was constructed in order to minimise distance
519 distortions. Minimum and maximum edge lengths were set to 25 and 500 km, respectively, and a 1000-km external
520 buffer was used to avoid artifacts at the edges of the spatial domain.(84) These values were chosen to yield denser
521 mesh vertices in data-rich areas while maximising the overall spatial field resolution, within computational
522 constraints. The spatial mesh is illustrated in Supplementary Figure 9.
523

524
525 **Supplementary Figure 9. Spatial mesh construction.**

526 Two-dimensional projection of spherical refined Delaunay triangulation mesh used in estimating spatial random
527 fields in Africa and Yemen, with national boundaries (bold lines). The mesh features greater vertex density in data-
528 rich locations.
529
530 **5.3.7 Model fitting and estimation generation**
531 Models were fit using the integrated nested Laplace approximation (INLA) algorithm in R-INLA. Fitted models for
532 each region were used to generate 1000 random samples from the joint posterior distributions of model parameters,
533 yielding mean and uncertainty estimates for onchocerciasis prevalence.
534
535 **5.3.8 Model results**
536 Model parameter estimates from the MBG model are summarised in Supplementary Table 8. Nominal range is the
537 distance (in km) at which spatial correlation has declined to about 0.1. Estimated random effects for the
538 environmental suitability covariate are displayed in Supplementary Figure 10.

539 **Supplementary Table 8. Parameter estimates from in-sample onchocerciasis MBG model.**

540 GP: Gaussian process. i.i.d.: Independent and identically distributed random effects. RW2: Second-order random
541 walk model.

Parameter	Median (95% UI)
Intercept	-3.656 (-4.214, -3.099)
GP nominal range	189.6 (176.7, 207.1)
GP nominal variance	3.177 (2.892, 3.568)
Nugget precision (i.i.d.)	0.719 (0.683, 0.742)
Country precision (i.i.d.)	0.505 (0.268, 0.992)
Environmental suitability precision (RW2)	32.269 (5.731, 125.009)
Covariate coefficients	
MDA (allmda)	-1.106 (-1.136, -1.077)
Diurnal temperature range (crutsdtr)	-0.363 (-0.537, -0.199)
Temperature (crutstmp)	-0.172 (-0.325, -0.018)
Wet day frequency (crutswet)	-0.163 (-0.315, -0.012)
Distance to rivers >25 m wide (distrivers25m)	-0.021 (-0.070, 0.028)
Enhanced Vegetation Index (evi_v6)	0.192 (0.129, 0.256)
Precipitation (mswep)	0.137 (0.057, 0.217)
Soil: Probability of bedrock exposure (sgbdrlog)	-0.063 (-0.119, -0.007)
Soil: Bulk density (200 cm depth) (sgbldfie)	0.100 (0.038, 0.163)
Soil: Clay content mass fraction (200 cm depth) (sgclyppt)	-0.078 (-0.157, 0.002)
Soil: Coarse fragments (200 cm depth) (sgcrfvol)	0.077 (0.008, 0.146)
Slope (slope)	0.008 (-0.021, 0.038)
Tasseled cap brightness (tcb_v6)	-0.333 (-0.404, -0.262)
Population (worldpop)	-0.014 (-0.037, 0.010)
River width (river_size)	0.072 (0.039, 0.106)

542
543

Supplementary Figure 10. Estimated random effects for environmental suitability.

Random effect estimates (mean and 95% UI) are shown for the environmental suitability layer, fit within INLA using a second-order random walk (RW2) model with standard-normalised suitability values (x-axis) grouped into 25 bins by quantile; y-axis values indicate effects in logit space.

5.3.9 *Loa loa* endemicity

The co-occurrence of *O. volvulus* and the filarial nematode *Loa loa* complicates onchocerciasis control in some parts of central Africa,(86,87) due to potentially severe complications from ivermectin treatment in individuals with high *L. loa* microfilariae loads.(88,89) Previous modelling studies have estimated the scale of co-infections between *O. volvulus* and *L. loa* and have suggested a substantial burden of co-infection or populations at risk.(90,91) We complemented these studies by calculating the mean number of onchocerciasis cases estimated by our geospatial model in 2018, in areas considered meso- or hyper-endemic for loiasis according to endemicity classifications from ESPEN. We obtained data from ESPEN for loiasis endemicity in 2015 at the level of Implementation Units and combined this with the WorldPop population raster and our onchocerciasis mean prevalence estimates, deriving a mean estimate of 7 146 618 onchocerciasis cases in loiasis-endemic areas (excluding hypo-endemic regions) in 2018.

5.4 Model validation

5.4.1 Metrics of predictive validity

In order to assess the predictive validity of our estimates, we validated our models using spatially stratified five-fold out-of-sample cross-validation. To construct each spatial fold, we used a modified bi-tree algorithm to spatially aggregate datapoints. This algorithm recursively partitions two-dimensional space, alternating between horizontal

568 and vertical splits on the weighted data sample size medians, until the data contained within each spatial partition are
569 of a similar sample size. The depth of recursive partitioning is constrained by the target sample size within a
570 partition and the minimum number of clusters or pseudo-clusters allowed within each spatial partition (in this case, a
571 minimum sample size of 500 was used). These spatial partitions are then allocated to one of five folds for cross-
572 validation. Temporal partitioning was unstructured (random).
573
574 For validation, each geostatistical model was run five times, each time holding out data from one of the folds. A set
575 of out-of-sample predictions were generated by sampling from the posterior predictive distribution for each held-out
576 datapoint. A full suite of out-of-sample predictions over the entire dataset was calculated by combining the out-of-
577 sample predictions from the five cross-validation runs. Using these out-of-sample predictions, we computed mean
578 error (bias), mean absolute error, 95% coverage of the predictive intervals (the proportion of observed out-of-sample
579 data that fall within the predicted 95% uncertainty intervals), root-mean squared error (RMSE, which summarises
580 error variance), and the correlation of predicted versus observed prevalence at the level of individual datapoints. A
581 scatterplot of reported prevalence versus mean out-of-sample predictions is provided in Supplementary Figure 11,
582 and validation metrics are summarised in Supplementary Table 9.
583
584 In addition to performing cross-validation, we also evaluated over-dispersion in the model input data by performing
585 posterior predictive checks. Briefly, a binomial count was simulated from each of 1,000 model draws of predictions
586 for each input data row. The distribution of predictions provided a good approximation of the observed distribution,
587 suggesting that the model is adequately addressing possible over-dispersion in the data.

40

Supplementary Figure 11. Model validation scatterplots for Africa and Yemen.

Reported prevalence versus mean out-of-sample predictions for individual datapoints, by year and country. Vertical bars represent 95% UI; red lines indicate equivalence.

593 **Supplementary Table 9. Out-of-sample validation metrics at the level of individual datapoints, from five-fold**
594 **cross-validation**

595 Out-of-sample performance was aggregated over 1988–2018 and is also provided for individual model years. Values
596 were computed in prevalence space. N observations: Number of data rows in the full dataset from a given year.
597 Mean abs. error: Mean absolute error. 95% cov.: 95% coverage. Corr.: Correlation.
598

Year	N Observations	Mean error	Mean abs. error	95% cov.	RMSE	Corr.
1988	216	0.158	0.257	0.837	0.298	0.298
1989	310	0.017	0.155	0.934	0.205	0.645
1990	232	-0.081	0.171	0.919	0.209	0.565
1991	58	0.159	0.317	0.639	0.407	-0.003
1992	983	0.040	0.130	0.961	0.174	0.658
1993	866	-0.005	0.175	0.920	0.233	0.554
1994	770	0.060	0.159	0.941	0.210	0.359
1995	58	-0.037	0.124	0.908	0.161	0.500
1996	1 104	0.021	0.093	0.967	0.144	0.709
1997	1 148	-0.008	0.138	0.959	0.189	0.745
1998	1 620	-0.023	0.109	0.970	0.152	0.615
1999	370	-0.052	0.074	0.942	0.126	0.575
2000	958	-0.026	0.089	0.978	0.123	0.814
2001	1 163	-0.010	0.112	0.954	0.163	0.707
2002	885	0.012	0.147	0.913	0.200	0.547
2003	1 082	0.017	0.119	0.953	0.173	0.615
2004	397	0.009	0.113	0.930	0.153	0.658
2005	1 930	0.005	0.144	0.965	0.188	0.533
2006	383	-0.002	0.104	0.727	0.170	0.611
2007	117	-0.017	0.046	0.899	0.083	0.631
2008	367	0.046	0.112	0.902	0.195	0.666
2009	193	-0.010	0.055	0.816	0.092	0.566
2010	133	0.020	0.066	0.904	0.097	0.722
2011	764	0.009	0.097	0.903	0.140	0.620

Year	N Observations	Mean error	Mean abs. error	95% cov.	RMSE	Corr.
2012	543	0.014	0.063	0.934	0.115	0.659
2013	477	-0.014	0.021	0.965	0.046	0.207
2014	397	-0.035	0.051	0.914	0.096	0.344
2015	472	-0.043	0.077	0.853	0.129	0.182
2016	96	0.004	0.033	0.955	0.075	0.138
2017	20	0.062	0.096	0.995	0.189	0.881
2018	4	-0.138	0.138	0.524	0.145	NA
1988–2018	18 116	0.003	0.111	0.924	0.168	0.706

599

6.0 Supplementary references

1. ESPEN. ESPEN. Available from: https://www.espen.org/

2. WHO | Geographical distribution of onchocerciasis. WHO. World Health Organization; Available from: https://www.who.int/onchocerciasis/distribution/en/

3. Remme JHF. The African programme for onchocerciasis control: preparing to launch. Parasitol Today. 1995;11(11):403–6.

4. Ngoumou P, Walsh JF, Mace JM. A rapid mapping technique for the prevalence and distribution of onchocerciasis: a Cameroon case study. Ann Trop Med Parasitol. 1994;88(5):463–74.

5. Ngoumou P, Walsh JF, Blindness WP for the P of, Diseases UBSP for R and T in T. A manual for rapid epidemiological mapping of onchocerciasis. 1993; Available from: https://apps.who.int/iris/handle/10665/59537

6. Noma M, Nwoke BEB, Nutall I, Tambala PA, Enyong P, Namsenmo A, et al. Rapid epidemiological mapping of onchocerciasis (REMO): its application by the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2002;96 Suppl 1:S29-39.

7. Tekle AH, Zouré HGM, Noma M, Boussinesq M, Coffeng LE, Stolk WA, et al. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infect Dis Poverty. 2016;5(1):66.

8. WHO | African Programme for Onchocerciasis Control: progress report, 2013–2014. Wkly Epidemiol Rec. 2014;89(49):551–60.

9. ENVISION. Tanzania Work Plan, FY2018. ENVISION; 2017. Available from: https://www.ntdenvision.org/sites/default/files/docs/tanzania_work_planfy18.pdf

10. de Smet E, Metanmo S, Mbelesso P, Kemata B, Siewe Fodjo JN, Boumédiène F, et al. Focus of ongoing onchocerciasis transmission close to Bangui, Central African Republic. Pathogens. 2020;9(5):337.

11. Bof JCM, Maketa V, Bakajika DK, Ntumba F, Mpunga D, Murdoch ME, et al. Onchocerciasis control in the Democratic Republic of Congo (DRC): challenges in a post-war environment. Trop Med Int Health. 2015;20(1):48–62.

12. Makenga Bof JC, Ntumba Tshitoka F, Muteba D, Mansiangi P, Coppieters Y. Review of the National Program for Onchocerciasis Control in the Democratic Republic of the Congo. Trop Med Infect Dis. 2019;4(2):92.

13. Samuel A, Belay T, Yehalaw D, Taha M, Zemene E, Zeynudin A. Impact of six years community directed treatment with ivermectin in the control of onchocerciasis, Western Ethiopia. PLOS ONE. 2016;11(3):e0141029.

14. Gemade EII, Jiya JY, Nwoke BEB, Ogunba EO, Edeghere H, Akoh JI, et al. Human onchocerciasis: current assessment of the disease burden in Nigeria by rapid epidemiological mapping. Ann Trop Med Parasitol. 1998;92(sup1):S79–83.

15. Republic of Rwanda Ministry of Health. Neglected Tropical Diseases Strategic Plan 2019-2024. Republic of Rwanda Ministry of Health; 2019. Available from: http://rbc.gov.rw/fileadmin/user_upload/guide2019/guide2019/RWANDA%20NTD%20STRATEGIC%20PLAN%202019-2024.pdf

16. Laggo MCL, Chane F. Onchocerciasis control in South Sudan. South Sudan Med J. 2011;4(3):61–2.

17. World Bank. Chad, Cameroon - Petroleum Development and Pipeline Project: environmental assessment. Washington, D.C.: World Bank; 1999. Available from: http://documents.banquemondiale.org/curated/fr/863021468769828252/pdf/multi-page.pdf

18. Katabarwa MN, Lakwo T, Habomugisha P, Unnasch TR, Garms R, Hudson-Davis L, et al. After 70 years of fighting an age-old scourge, onchocerciasis in Uganda, the end is in sight. Int Health. 2018;10(suppl_1):i79–88.

19. ESPEN Portal. Available from: https://admin.espen.afro.who.int/

20. WHO | Global Programme to Eliminate Lymphatic Filariasis. WHO. World Health Organization; Available from: http://www.who.int/lymphatic_filariasis/elimination-programme/en/

21. Graham MH. Confronting Multicollinearity in Ecological Multiple Regression. Ecology. 2003;84(11):2809–15.

658   22.   Faraway JJ. Linear Models with R. Boca Raton: CRC Press; 2005.

659   23.   Prost A, Thylefors B, Pairault C. Methods of mass epidemiological evaluation of
660   onchocerciasis: their utilization in a vector control programme. Expert Comm Epidemiol
661   Onchocerciasis. 1975;20.

662   24.   O'Hanlon SJ, Slater HC, Cheke RA, Boatin BA, Coffeng LE, Pion SDS, et al. Model-based
663   geostatistical mapping of the prevalence of Onchocerca volvulus in West Africa. PLoS
664   Negl Trop Dis. 2016;10(1):e0004328.

665   25.   World Health Organization. Supplemental Guidelines for Rapid Epidemiological Mapping
666   of Onchocerciasis (REMO). Geneva, Switzerland: World Health Organization; 1995.
667   Report No.: Document TDR/TDF/ONCHO/95.1. Available from:
668   https://www.who.int/tdr/publications/tdr-research-publications/oncho-guidelines/en/

669   26.   Zouré HG, Noma M, Tekle AH, Amazigo UV, Diggle PJ, Giorgi E, et al. The geographic
670   distribution of onchocerciasis in the 20 participating countries of the African Programme
671   for Onchocerciasis Control: (2) pre-control endemicity levels and estimated number
672   infected. Parasit Vectors. 2014;7(1):326.

673   27.   Gallin M, Adams A, Kruppa TF, Gbaguidi EA, Massougbodji A, Sadeler BC, et al.
674   Epidemiological studies of onchocerciasis in southern Benin. Trop Med Parasitol Off Organ
675   Dtsch Tropenmedizinische Ges Dtsch Ges Tech Zusammenarbeit GTZ. 1993;44(2):69–74.

676   28.   Boussinesq M, Chippaux JP, Ernould JC, Quillevere D, Prod'hon J. Effect of repeated
677   treatments with ivermectin on the incidence of onchocerciasis in northern Cameroon. Am J
678   Trop Med Hyg. 1995;53(1):63–7.

679   29.   Mendoza Aldana J, Piechulek H, Maguire J. Forest onchocerciasis in Cameroon: its
680   distribution and implications for selection of communities for control programmes. Ann
681   Trop Med Parasitol. 1997;91(1):79–86.

682   30.   Katabarwa MN, Eyamba A, Nwane P, Enyong P, Kamgno J, Kueté T, et al. Fifteen years of
683   annual mass treatment of onchocerciasis with ivermectin have not interrupted transmission
684   in the west region of Cameroon. J Parasitol Res. 2013;2013. Available from:
685   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652197/

686   31.   Kamgno J, Boussinesq M. Hyperendemic loaiasis in the Tikar plain, shrub savanna region
687   of Cameroon. Bull Soc Pathol Exot 1990. 2001;94(4):342–6.

688   32.   Katabarwa MN, Eyamba A, Chouaibou M, Enyong P, Kuété T, Yaya S, et al. Does
689   onchocerciasis transmission take place in hypoendemic areas? a study from the North
690   Region of Cameroon. Trop Med Int Health. 2010;15(5):645–52.

691   33.   Katabarwa MN, Eyamba A, Nwane P, Enyong P, Yaya S, Baldiagaï J, et al. Seventeen
692   years of annual distribution of ivermectin has not interrupted onchocerciasis transmission in
693   North Region, Cameroon. Am J Trop Med Hyg. 2011;85(6):1041–9.

34. Kamga HLF, Shey DN, Assob JCN, Njunda AL, Nde Fon P, Njem PK. Prevalence of onchocerciasis in the Fundong Health District, Cameroon after 6 years of continuous community-directed treatment with ivermectin. Pan Afr Med J. 2011;10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240934/

35. Wanji S, Kengne-Ouafo JA, Esum ME, Chounna PWN, Adzemye BF, Eyong JEE, et al. Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in Cameroon. Parasit Vectors. 2015;8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696282/

36. Kamga GR, Dissak-Delon FN, Nana-Djeunga HC, Biholong BD, Ghogomu SM, Souopgui J, et al. Important progress towards elimination of onchocerciasis in the West Region of Cameroon. Parasit Vectors. 2017;10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543544/

37. Kamga GR, Dissak-Delon FN, Nana-Djeunga HC, Biholong BD, Mbigha-Ghogomu S, Souopgui J, et al. Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment. Parasit Vectors. 2016;9(1):581.

38. Bakajika D, Senyonjo L, Enyong P, Oye J, Biholong B, Elhassan E, et al. On-going transmission of human onchocerciasis in the Massangam health district in the West Region of Cameroon: Better understanding transmission dynamics to inform changes in programmatic interventions. PLoS Negl Trop Dis. 2018;12(11):e0006904.

39. Katabarwa M, Eyamba A, Habomugisha P, Lakwo T, Ekobo S, Kamgno J, et al. After a decade of annual dose mass ivermectin treatment in Cameroon and Uganda, onchocerciasis transmission continues. Trop Med Int Health TM IH. 2008;13(9):1196–203.

40. Kennedy MH, Bertocchi I, Hopkins AD, Meredith SE. The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Ann Trop Med Parasitol. 2002;96(3):297–307.

41. Taye A, Gebre-Michael T, Taticheff S. Onchocerciasis in Gilgel Ghibe River Valley southwest Ethiopia. East Afr Med J. 2000;77(2):116–20.

42. Mengistu G, Balcha F, Britton S. Co-infection of Onchocerca volvulus and intestinal helminths in indigenous and migrant farmers in southwest Ethiopia. Ethiop Med J. 2002;40(1):19–27.

43. Legesse M, Balcha F, Erko B. Status of onchocerciasis in Teppi area, Southwestern Ethiopia, after four years of annual community-directed treatment with ivermectin. Ethiop J Health Dev. 2010;24(1). Available from: https://www.ajol.info/index.php/ejhd/article/view/62945

731 44. Dori GU, Belay T, Belete H, Panicker KN, Hailu A. Parasitological and clinico-
732 epidemiological features of onchocerciasis in West Wellega, Ethiopia. J Parasit Dis Off
733 Organ Indian Soc Parasitol. 2012;36(1):10–8.

734 45. Dana D, Debalke S, Mekonnen Z, Kassahun W, Suleman S, Getahun K, et al. A
735 community-based cross-sectional study of the epidemiology of onchocerciasis in unmapped
736 villages for community directed treatment with ivermectin in Jimma Zone, southwestern
737 Ethiopia. BMC Public Health. 2015;15:595.

738 46. Fobi G, Mourou Mbina JR, Ozoh G, Kombila M, Agaya C, Olinga Olinga JM, et al.
739 Onchocerciasis in the area of Lastourville, Gabon. Clinical and entomological aspects. Bull
740 Soc Pathol Exot 1990. 2006;99(4):269–71.

741 47. Anosike JC, Onwuliri CO. Studies on filariasis in Bauchi State, Nigeria. II. The prevalence
742 of human filariasis in Darazo Local Government area. Appl Parasitol. 1994;35(4):242–50.

743 48. Osue HO, Inabo HI, Yakubu SE, Audu PA, Galadima M, Odama LE, et al. Impact of
744 eighteen-year varied compliance to onchocerciasis treatment with ivermectin in sentinel
745 savannah agrarian communities in Kaduna State of Nigeria. ISRN Parasitol.
746 2013;2013:960168.

747 49. Anosike JC, Celestine null, Onwuliri OE, Onwuliri VA. The prevalence, intensity and
748 clinical manifestations of Onchocerca volvulus infection in Toro local government area of
749 Bauchi State, Nigeria. Int J Hyg Environ Health. 2001;203(5–6):459–64.

750 50. Umeh RE. The causes and profile of visual loss in an onchocerciasis-endemic forest-
751 savanna zone in Nigeria. Ophthalmic Epidemiol. 1999;6(4):303–15.

752 51. Nmorsi OPG, Oladokun I a. A, Egwunyenga OA, Oseha E. Eye lesions and onchocerciasis
753 in a rural farm settlement in Delta state, Nigeria. Southeast Asian J Trop Med Public
754 Health. 2002;33(1):28–32.

755 52. Okoye IC, Onwuliri CO. Epidemiology and psycho-social aspects of onchocercal skin
756 diseases in northeastern Nigeria. Filaria J. 2007;6:15.

757 53. Rebecca SN, Akinboye DO, Abdulazeez AA. Onchocerciasis and plasmodiasis: concurrent
758 infection in Garaha-Dutse community, Adamawa State Nigeria. Biomed Res. 2008;19(2).
759 Available from: https://www.alliedacademies.org/abstract/onchocerciasis-and-
760 plasmodiasis-concurrent-infectionrnin-garahadutse-community-adamawa-state-nigeria-
761 802.html

762 54. Emukah E, Nimzing J, Ezeabikwa M, Obiezu J, Okpala N, Miri E, et al. Impact assessment
763 of repeated annual ivermectin on ocular and clinical onchocerciasis 14 years of annual mass
764 drug administration in eight sentinel villages, southeast Nigeria. Am J Trop Med Hyg.
765 2010;83(Suppl 5):22.

766 55. Akinbo FO, Okaka CE. Hyperendemicity of onchocerciasis in Ovia Northeast Local
767 Government Area, Edo State, Nigeria. East Afr J Public Health. 2010;7(1):84–6.

768   56. Akinboye, D.O, Okwong, E, N A, Agbolade FO, et al. Onchocerciasis among inhabitants of
769   Ibarapa local government community of Oyo state, Nigeria. Biomed Res. 2010;21(2).
770   Available from: https://www.alliedacademies.org/abstract/onchocerciasis-among-
771   inhabitants-of-ibarapa-local-governmentrncommunity-of-oyo-state-nigeria-1287.html

772   57. Uttah E, Ibeh DC. Multiple filarial species microfilaraemia: a comparative study of areas
773   with endemic and sporadic onchocerciasis. J Vector Borne Dis. 2011;48(4):197–204.

774   58. Evans DS, Alphonsus K, Umaru J, Eigege A, Miri E, Mafuyai H, et al. Status of
775   onchocerciasis transmission after more than a decade of mass drug administration for
776   onchocerciasis and lymphatic filariasis elimination in Central Nigeria: challenges in
777   coordinating the Stop MDA Decision. PLoS Negl Trop Dis. 2014;8(9). Available from:
778   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169246/

779   59. Eyo J, Onyishi G, Ugokwe C. Rapid epidemiological assessment of onchocerciasis in a
780   tropical semi-urban community, enugu state, Nigeria. Iran J Parasitol. 2013;8(1):145–51.

781   60. Koroma JB, Sesay S, Conteh A, Koudou B, Paye J, Bah M, et al. Impact of five annual
782   rounds of mass drug administration with ivermectin on onchocerciasis in Sierra Leone.
783   Infect Dis Poverty. 2018;7(1):30.

784   61. Dogba PK, Komi BT. The evaluation of endemic onchocerciasis in the Amou prefecture
785   (Togo). Bull Soc Pathol Exot 1990. 1994;87(2):110–1.

786   62. Golden A, Faulx D, Kalnoky M, Stevens E, Yokobe L, Peck R, et al. Analysis of age-
787   dependent trends in Ov16 IgG4 seroprevalence to onchocerciasis. Parasit Vectors.
788   2016;9(1):338.

789   63. Komlan K, Vossberg PS, Gantin RG, Solim T, Korbmacher F, Banla M, et al. Onchocerca
790   volvulus infection and serological prevalence, ocular onchocerciasis and parasite
791   transmission in northern and central Togo after decades of Simulium damnosum s.l. vector
792   control and mass drug administration of ivermectin. PLoS Negl Trop Dis.
793   2018;12(3):e0006312.

794   64. Katabarwa MN, Lakwo T, Habomugisha P, Agunyo S, Byamukama E, Oguttu D, et al.
795   Transmission of Onchocerca volvulus continues in Nyagak-Bondo focus of northwestern
796   Uganda after 18 years of a single dose of annual treatment with ivermectin. Am J Trop Med
797   Hyg. 2013;89(2):293–300.

798   65. Luroni LT, Gabriel M, Tukahebwa E, Onapa AW, Tinkitina B, Tukesiga E, et al. The
799   interruption of Onchocerca volvulus and Wuchereria bancrofti transmission by integrated
800   chemotherapy in the Obongi focus, North Western Uganda. PloS One.
801   2017;12(12):e0189306.

802   66. Murray CJL, Callender CSKH, Kulikoff XR, Srinivasan V, Abate D, Abate KH, et al.
803   Population and fertility by age and sex for 195 countries and territories, 1950–2017: a
804   systematic analysis for the Global Burden of Disease Study 2017. The Lancet.
805   2018;392(10159):1995–2051.

806   67.   Ramsay JO, Wickham H, Graves S, Hooker G. fda: Functional Data Analysis. 2018.
807   Available from: https://CRAN.R-project.org/package=fda

808   68.   Byrd RH, Lu P, Nocedal J, Zhu C. A limited memory algorithm for bound constrained
809   optimization. SIAM J Sci Comput. 1995;16(5):1190–208.

810   69.   R: The R Project for Statistical Computing. Available from: https://www.r-project.org/

811   70.   Kirkwood B, Smith P, Marshall T, Prost A. Variations in the prevalence and intensity of
812   microfilarial infections by age, sex, place and time in the area of the Onchocerciasis Control
813   Programme. Trans R Soc Trop Med Hyg. 1983;77(6):857–61.

814   71.   Vivas-Martínez S, Basáñez MG, Botto C, Rojas S, García M, Pacheco M, et al. Amazonian
815   onchocerciasis: parasitological profiles by host-age, sex, and endemicity in southern
816   Venezuela. Parasitology. 2000;121(5):513–25.

817   72.   Anderson RM, Basáñez MG, Boussinesq M. Population biology of human onchocerciasis.
818   Philos Trans R Soc Lond B Biol Sci. 1999;354(1384):809–26.

819   73.   Coffeng LE, Pion SDS, O'Hanlon S, Cousens S, Abiose AO, Fischer PU, et al.
820   Onchocerciasis: the pre-control association between prevalence of palpable nodules and
821   skin microfilariae. PLoS Negl Trop Dis. 2013;7(4):e2168.

822   74.   Hamley JID, Milton P, Walker M, Basáñez MG. Modelling exposure heterogeneity and
823   density dependence in onchocerciasis using a novel individual-based transmission model,
824   EPIONCHO-IBM: Implications for elimination and data needs. PLoS Negl Trop Dis.
825   2019;13(12):e0007557.

826   75.   Gebrezgabiher G, Mekonnen Z, Yewhalaw D, Hailu A. Reaching the last mile: main
827   challenges relating to and recommendations to accelerate onchocerciasis elimination in
828   Africa. Infect Dis Poverty. 2019;8(1):60.

829   76.   Vlaminck J, Fischer PU, Weil GJ. Diagnostic tools for onchocerciasis elimination
830   programs. Trends Parasitol. 2015;31(11):571–82.

831   77.   Turner HC, Walker M, Churcher TS, Basáñez MG. Modelling the impact of ivermectin on
832   River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho
833   projections. Parasit Vectors. 2014;7(1):241.

834   78.   Remme. The global burden of onchocerciasis in 1990. Geneva, Switzerland: World Health
835   Organization; 2004 p. 26. Available from:
836   https://www.who.int/apoc/publications/bod_onchocerciasis1990_the_global_burden_of_on
837   chocerciasis_in_1990.pdf

838   79.   Unnasch TR, Golden A, Cama V, Cantey PT. Diagnostics for onchocerciasis in the era of
839   elimination. Int Health. 2018;10(suppl_1):i20–6.

80. Golding N, Burstein R, Longbottom J, Browne AJ, Fullman N, Osgood-Zimmerman A, et al. Mapping under-5 and neonatal mortality in Africa, 2000–15: a baseline analysis for the Sustainable Development Goals. The Lancet. 2017;390(10108):2171–82.

81. Cromwell EA, Osborne JCP, Unnasch TR, Basáñez MG, Gass KM, Barbre KA, et al. Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning. PLoS Negl Trop Dis. 2021;15(7):e0008824.

82. Gómez-Rubio V, Palmí-Perales F. Multivariate posterior inference for spatial models with the integrated nested Laplace approximation. J R Stat Soc Ser C Appl Stat. 2019;68(1):199–215.

83. Lindgren F, Rue H, Lindström J. An explicit link between Gaussian fields and Gaussian Markov random fields: the stochastic partial differential equation approach. Stat Methodol Ser B. 2011;73(4):423–98.

84. Blangiardo M, Cameletti M, Baio G, Rue H. Spatial and spatio-temporal models with R-INLA. Spat Spatio-Temporal Epidemiol. 2013;7:39–55.

85. Lindgren F, Rue H. Bayesian Spatial Modelling with R- INLA. J Stat Softw. 2015;63(19):1–25.

86. Wanji S, Ndongmo WPC, Fombad FF, Kengne-Ouafo JA, Njouendou AJ, Tchounkeu YFL, et al. Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa. PLoS Negl Trop Dis. 2018;12(9):e0006750.

87. Zouré HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the rapid assessment procedure for loiasis (RAPLOA). PLoS Negl Trop Dis. 2011;5(6):e1210.

88. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. The Lancet. 1997;350(9070):18–22.

89. Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J. 2003;2(1):S4.

90. Vinkeles Melchers NVS, Coffeng LE, Boussinesq M, Pedrique B, Pion SDS, Tekle AH, et al. Projected number of people with onchocerciasis–loiasis coinfection in Africa, 1995 to 2025. Clin Infect Dis. 2020;70(11):2281–9.

91. Cano J, Basáñez MG, O'Hanlon SJ, Tekle AH, Wanji S, Zouré HG, et al. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns. Parasit Vectors. 2018;11(1):70.

877

7.0 LBD 2019 Neglected Tropical Diseases Collaborators

Chris A Schmidt,[1] Elizabeth A Cromwell,[1,2] Elex Hill,[1] Katie M Donkers,[1] Megan F Schipp,[1] Kimberly B Johnson,[1] David M Pigott,[1,2] Jaffar Abbas,[3] Victor Adekanmbi,[4] Olatunji O Adetokunboh,[5,6] Muktar Beshir Ahmed,[7,8] Fahad Mashhour Alanezi,[9] Turki M Alanzi,[10] Vahid Alipour,[11,12] Catalina Liliana Andrei,[13] Prof Tudorel Andrei,[14] Davood Anvari,[15,16] Seth Christopher Yaw Appiah,[17,18] Muhammad Aqeel,[19,19] Jalal Arabloo,[11] Prof Mohammad Asghari-Jafarabadi,[20,21] Prof Marcel Ausloos,[22,14] Atif Amin Baig,[23] Prof Maciej Banach,[24,25] Prof Till Winfried Bärnighausen,[26,27] Krittika Bhattacharyya,[28,29] Prof Zulfiqar A Bhutta,[30,31] Ali Bijani,[32] Oliver J Brady,[33] Nicola Luigi Bragazzi,[34] Zahid A Butt,[35,36] Prof Felix Carvalho,[37] Vijay Kumar Chattu,[38,39] Saad M A Dahlawi,[40] Giovanni Damiani,[41,42] Feleke Mekonnen Demeke,[43] Kebede Deribe,[44,45] Prof Samath Dhamminda Dharmaratne,[46,2,1] Prof Daniel Diaz,[47,48] Alireza Didarloo,[49] Lucas Earl,[1] Prof Maysaa El Sayed Zaki,[50] Prof Maha El Tantawi,[51] Nazir Fattahi,[52] Prof Eduarda Fernandes,[53] Nataliya A Foigt,[54] Masoud Foroutan,[55,56] Richard Charles Franklin,[57] Prof Yuming Guo,[58,59] Arvin Haj-Mirzaian,[60,61] Prof Samer Hamidi,[62] Hadi Hassankhani,[63,64] Prof Claudiu Herteliu,[14,65] Prof Tarig B Higazi,[66] Prof Mostafa Hosseini,[67,68] Mehdi Hosseinzadeh,[69,70] Prof Mowafa Househ,[71] Olayinka Stephen Ilesanmi,[72,73] Irena M Ilic,[74] Prof Milena D Ilic,[75] Seyed Sina Naghibi Irvani,[61] Ravi Prakash Jha,[76,77] John S Ji,[78] Prof Jost B Jonas,[79,80] Jacek Jerzy Jozwiak,[81] Leila R Kalankesh,[82] Naser Kamyari,[83] Prof Behzad Karami Matin,[52] Salah Eddin Karimi,[84] Gbenga A Kayode,[85,86] Ali Kazemi Karyani,[52] Ejaz Ahmad Khan,[87] Md Nuruzzaman Khan,[88] Khaled Khatab,[89,90] Mona M Khater,[91] Neda Kianipour,[92] Yun Jin Kim,[93] Soewarta Kosen,[94] Dian Kusuma,[95,96] Prof Carlo La Vecchia,[97] Prof Van Charles Lansingh,[98,99] Paul H Lee,[100] Shanshan Li,[101] Shokofeh Maleki,[102] Mohammad Ali Mansournia,[67] Francisco Rogerlândio Martins-Melo,[103] Colm McAlinden,[104] Walter Mendoza,[105] Tomislav Mestrovic,[106,107] Masoud Moghadaszadeh,[108,109] Abdollah Mohammadian-Hafshejani,[110] Seyyede Momeneh Mohammadi,[111] Shafiu Mohammed,[112,113] Rahmatollah Moradzadeh,[114] Paula Moraga,[115] Mehdi Naderi,[102] Ahamarshan Jayaraman Nagarajan,[116,117] Ionut Negoi,[118,119] Cuong Tat Nguyen,[120] Huong Lan Thi Nguyen,[120] Prof Bogdan Oancea,[121] Andrew T Olagunju,[122,123] Ahmed Omar Bali,[124] Prof Obinna E Onwujekwe,[125] Adrian Pana,[14,126] Prof Vafa Rahimi-Movaghar,[127] Kiana Ramezanzadeh,[60] David Laith Rawaf,[128,129] Prof Salman Rawaf,[130,131] Reza Rawassizadeh,[132] Aziz Rezapour,[11] Ana Isabel Ribeiro,[133] Abdallah M Samy,[134] Masood Ali Shaikh,[135] Kiomars Sharafi,[52] Prof Aziz Sheikh,[136,137] Prof Jasvinder A Singh,[138,139] Eirini Skiadaresi,[140] Shahin Soltani,[52] Wilma A Stolk,[141] Mu'awiyyah Babale Sufiyan,[142] Alan J Thomson,[143] Bach Xuan Tran,[144] Khanh Bao Tran,[145,146] Prof Bhaskaran Unnikrishnan,[147] Prof Francesco S Violante,[148,149] Giang Thu Vu,[150] Tomohide Yamada,[151] Prof Sanni Yaya,[152,153] Prof Paul Yip,[154,155] Naohiro Yonemoto,[156,157] Prof Chuanhua Yu,[158] Yong Yu,[159] Maryam Zamanian,[114] Yunquan Zhang,[160,161] Zhi-Jiang Zhang,[162] Arash Ziapour,[163] Prof Simon I Hay.[1,2]

Affiliations

[1]Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; [2]Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA; [3]Antai College of Economics, Shanghai Jiao Tong University, Shanghai, China; [4]Department of Population Medicine, Cardiff University, Cardiff, UK; [5]DSI-NRF Centre of Excellence for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa; [6]Division of Epidemiology & Biostatistics, Stellenbosch University, Cape Town, South Africa; [7]Department of Epidemiology, Jimma University, Jimma, Ethiopia; [8]Australian Center for Precision Health, University of South Australia, Adelaide, SA, Australia; [9]Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; [10]Health Information Management and Technology Department, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; [11]Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran; [12]Department of Health Economics, Iran University of Medical Sciences, Tehran, Iran; [13]Cardiology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; [14]Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania; [15]Department of Parasitology, Mazandaran University of Medical Sciences, Sari, Iran; [16]Department of Parasitology, Iranshahr University of Medical Sciences, Iranshahr, Iran; [17]Department of Sociology and Social Work, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; [18]Center for International Health, Ludwig Maximilians University, Munich, Germany; [19]Department of Psychology, Foundation University Islamabad, Rawalpandi, Pakistan; [20]Department of Biostatistics and Epidemiology, Tabriz University of Medical Sciences, Tabriz, Iran; [21]Department of Biostatistics and Epidemiology, Zanjan University of Medical Sciences, Zanjan, Iran; [22]School of Business, University of Leicester, Leicester, UK; [23]Unit of Biochemistry,

52

931   Universiti Sultan Zainal Abidin (Sultan Zainal Abidin University), Kuala Terengganu, Malaysia;
932   [24]Department of Hypertension, Medical University of Lodz, Lodz, Poland; [25]Polish Mothers' Memorial
933   Hospital Research Institute, Lodz, Poland; [26]Heidelberg Institute of Global Health (HIGH), Heidelberg
934   University, Heidelberg, Germany; [27]T.H. Chan School of Public Health, Harvard University, Boston, MA,
935   USA; [28]Department of Statistical and Computational Genomics, National Institute of Biomedical Genomics,
936   Kalyani, India; [29]Department of Statistics, University of Calcutta, Kolkata, India; [30]Centre for Global Child
937   Health, University of Toronto, Toronto, ON, Canada; [31]Centre of Excellence in Women & Child Health, Aga
938   Khan University, Karachi, Pakistan; [32]Social Determinants of Health Research Center, Babol University of
939   Medical Sciences, Babol, Iran; [33]Department of Infectious Disease Epidemiology, London School of Hygiene
940   & Tropical Medicine, London, UK; [34]University of Genoa, Genoa, Italy; [35]School of Public Health and Health
941   Systems, University of Waterloo, Waterloo, ON, Canada; [36]Al Shifa School of Public Health, Al Shifa Trust
942   Eye Hospital, Rawalpindi, Pakistan; [37]Research Unit on Applied Molecular Biosciences (UCIBIO), University
943   of Porto, Porto, Portugal; [38]Department of Community Medicine, Datta Meghe Institute of Medical Sciences,
944   Sawangi, India; [39]Saveetha Medical College, Saveetha University, Chennai, India; [40]Environmental Health
945   Department, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; [41]IRCCS Istituto Ortopedico
946   Galeazzi (Galeazzi Orthopedic Institute IRCCS), University of Milan, Milan, Italy; [42]Department of
947   Dermatology, Case Western Reserve University, Cleveland, OH, USA; [43]Department of Medical Laboratory
948   Sciences, Bahir Dar University, Bahir Dar, Ethiopia; [44]Wellcome Trust Brighton and Sussex Centre for Global
949   Health Research, Brighton and Sussex Medical School, Brighton, UK; [45]School of Public Health, Addis
950   Ababa University, Addis Ababa, Ethiopia; [46]Department of Community Medicine, University of Peradeniya,
951   Peradeniya, Sri Lanka; [47]Center of Complexity Sciences, National Autonomous University of Mexico, Mexico
952   City, Mexico; [48]Faculty of Veterinary Medicine and Zootechnics, Autonomous University of Sinaloa,
953   Culiacán Rosales, Mexico; [49]Department of Community Medicine and Public Health, Urmia University of
954   Medical Science, Urmia, Iran; [50]Reference Laboratory of Egyptian Universities Cairo, Ministry of Higher
955   Education and Scientific Research, Cairo, Egypt; [51]Pediatric Dentistry and Dental Public Health Department,
956   Alexandria University, Alexandria, Egypt; [52]Research Center for Environmental Determinants of Health,
957   Kermanshah University of Medical Sciences, Kermanshah, Iran; [53]Associated Laboratory for Green
958   Chemistry (LAQV), University of Porto, Porto, Portugal; [54]Institute of Gerontology, National Academy of
959   Medical Sciences of Ukraine, Kyiv, Ukraine; [55]Department of Medical Parasitology, Abadan University of
960   Medical Sciences, Abadan, Iran; [56]Faculty of Medicine, Abadan University of Medical Sciences, Abadan,
961   Iran; [57]School of Public Health, Medical, and Veterinary Sciences, James Cook University, Douglas, QLD,
962   Australia; [58]Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC,
963   Australia; [59]Department of Epidemiology, Binzhou Medical University, Yantai City, China; [60]Department of
964   Pharmacology, Shahid Beheshti University of Medical Sciences, Tehran, Iran; [61]Obesity Research Center,
965   Shahid Beheshti University of Medical Sciences, Tehran, Iran; [62]School of Health and Environmental Studies,
966   Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates; [63]School of Nursing and
967   Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran; [64]Independent Consultant, Tabriz, Iran;
968   [65]School of Business, London South Bank University, London, UK; [66]Department of Biological Sciences,
969   Ohio University, Zanesville, OH, USA; [67]Department of Epidemiology and Biostatistics, Tehran University of
970   Medical Sciences, Tehran, Iran; [68]Pediatric Chronic Kidney Disease Research Center, Tehran University of
971   Medical Sciences, Tehran, Iran; [69]Institute of Research and Development, Duy Tan University, Da Nang,
972   Vietnam; [70]Department of Computer Science, University of Human Development, Sulaymaniyah, Iraq;
973   [71]College of Science and Engineering, Hamad Bin Khalifa University, Doha, Qatar; [72]Department of
974   Community Medicine, University of Ibadan, Ibadan, Nigeria; [73]Department of Community Medicine,
975   University College Hospital, Ibadan, Ibadan, Nigeria; [74]Faculty of Medicine, University of Belgrade,
976   Belgrade, Serbia; [75]Department of Epidemiology, University of Kragujevac, Kragujevac, Serbia;
977   [76]Department of Community Medicine, Dr. Baba Saheb Ambedkar Medical College & Hospital, Delhi, India;
978   [77]Department of Community Medicine, Banaras Hindu University, Varanasi, India; [78]Vanke School of Public
979   Health, Tsinghua University, Beijing, China; [79]Institute of Molecular and Clinical Ophthalmology Basel,
980   Switzerland, Basel, Switzerland; [80]Department of Ophthalmology, Heidelberg University, Mannheim,
981   Germany; [81]Department of Family Medicine and Public Health, University of Opole, Opole, Poland; [82]School
982   of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran; [83]Department
983   of Biostatistics, Abadan University of Medical Sciences, Abadan, Iran; [84]Social Determinants of Health
984   Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; [85]International Research Center of
985   Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria; [86]Julius Centre for Health Sciences and
986   Primary Care, Utrecht University, Utrecht, Netherlands; [87]Department of Epidemiology and Biostatistics,

Health Services Academy, Islamabad, Pakistan; [88]Department of Population Science, Jatiya Kabi Kazi Nazrul Islam University, Mymensingh, Bangladesh; [89]Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK; [90]College of Arts and Sciences, Ohio University, Zanesville, OH, USA; [91]Department of Medical Parasitology, Cairo University, Cairo, Egypt; [92]Department of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran; [93]School of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang, Malaysia; [94]Independent Consultant, Jakarta, Indonesia; [95]Imperial College Business School, Imperial College London, London, UK; [96]Faculty of Public Health, University of Indonesia, Depok, Indonesia; [97]Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; [98]HelpMeSee, New York, NY, USA; [99]Mexican Institute of Ophthalmology, Queretaro, Mexico; [100]Department of Health Sciences, University of Leicester, Leicester, UK; [101]School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; [102]Clinical Research Development Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; [103]Campus Caucaia, Federal Institute of Education, Science and Technology of Ceará, Caucaia, Brazil; [104]Department of Ophthalmology, Singleton Hospital, Swansea, UK; [105]Peru Country Office, United Nations Population Fund (UNFPA), Lima, Peru; [106]Clinical Microbiology and Parasitology Unit, Dr. Zora Profozic Polyclinic, Zagreb, Croatia; [107]University Centre Varazdin, University North, Varazdin, Croatia; [108]Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; [109]Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; [110]Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran; [111]Department of Anatomical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran; [112]Health Systems and Policy Research Unit, Ahmadu Bello University, Zaria, Nigeria; [113]Department of Health Care Management, Technical University of Berlin, Berlin, Germany; [114]Department of Epidemiology, Arak University of Medical Sciences, Arak, Iran; [115]Computer, Electrical, and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia; [116]Research and Analytics Department, Initiative for Financing Health and Human Development, Chennai, India; [117]Department of Research and Analytics, Bioinsilico Technologies, Chennai, India; [118]Department of General Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; [119]Department of General Surgery, Emergency Hospital of Bucharest, Bucharest, Romania; [120]Institute for Global Health Innovations, Duy Tan University, Hanoi, Vietnam; [121]Administrative and Economic Sciences Department, University of Bucharest, Bucharest, Romania; [122]Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada; [123]Department of Psychiatry, University of Lagos, Lagos, Nigeria; [124]Diplomacy and Public Relations Department, University of Human Development, Sulaymaniyah, Iraq; [125]Department of Pharmacology and Therapeutics, University of Nigeria Nsukka, Enugu, Nigeria; [126]Department of Health Metrics, Center for Health Outcomes & Evaluation, Bucharest, Romania; [127]Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran; [128]WHO Collaborating Centre for Public Health Education and Training, Imperial College London, London, UK; [129]University College London Hospitals, London, UK; [130]Department of Primary Care and Public Health, Imperial College London, London, UK; [131]Academic Public Health England, Public Health England, London, UK; [132]Department of Computer Science, Boston University, Boston, MA, USA; [133]Epidemiology Research Unit (EPIUnit), University of Porto, Porto, Portugal; [134]Department of Entomology, Ain Shams University, Cairo, Egypt; [135]Independent Consultant, Karachi, Pakistan; [136]Centre for Medical Informatics, University of Edinburgh, Edinburgh, UK; [137]Division of General Internal Medicine, Harvard University, Boston, MA, USA; [138]School of Medicine, University of Alabama at Birmingham, Birmingham, AL, UK; [139]Medicine Service, US Department of Veterans Affairs (VA), Birmingham, AL, USA; [140]Department of Ophthalmology, Hywel Dda University Health Board, Llanelli, UK; [141]Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands; [142]Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria; [143]Department of Global Health Research, Adaptive Knowledge Management, Victoria, BC, Canada; [144]Department of Health Economics, Hanoi Medical University, Hanoi, Vietnam; [145]Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand; [146]Clinical Hematology and Toxicology, Maurice Wilkins Centre, Auckland, New Zealand; [147]Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, India; [148]Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; [149]Occupational Health Unit, Sant'Orsola Malpighi Hospital, Bologna, Italy; [150]Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam; [151]Department of Diabetes and Metabolic Diseases, University of Tokyo, Tokyo, Japan; [152]School of International Development and Global Studies, University of Ottawa, Ottawa, ON, Canada; [153]The George Institute for Global Health, University of Oxford, Oxford, UK; [154]Centre for Suicide Research and Prevention, University of Hong Kong, Hong Kong, China; [155]Department of Social Work and Social Administration,

54

University of Hong Kong, Hong Kong, China; [156]Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Kodaira, Japan; [157]Department of Public Health, Juntendo University, Tokyo, Japan; [158]Department of Epidemiology and Biostatistics, Wuhan University, Wuhan, China; [159]School of Public Health and Management, Hubei University of Medicine, Shiyan, China; [160]School of Public Health, Wuhan University of Science and Technology, Wuhan, China; [161]Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan, China; [162]School of Medicine, Wuhan University, Wuhan, China; [163]Department of Health Education and Health Promotion, Kermanshah University of Medical Sciences, Kermanshah, Iran.

8.0 Author contributions

Managing the estimation or publications process

Elizabeth A. Cromwell, Megan Schipp, Chris A. Schmidt, David M. Pigott, Simon I. Hay

Writing the first draft of the manuscript

Elizabeth A. Cromwell, Chris A. Schmidt, Elex Hill, Katie Donkers

Primary responsibility for applying analytical methods to produce estimates

Chris A. Schmidt, Elex Hill

Primary responsibility for seeking, cataloguing, extracting, or cleaning data; designing or coding figures and tables

Katie Donkers, Elex Hill, Chris A. Schmidt, Kim Johnson, David M. Pigott, Elizabeth A. Cromwell

Providing data or critical feedback on data sources

Kimberly B Johnson, Jaffar Abbas, Victor Adekanmbi, Olatunji O Adetokunboh, Muktar Beshir Ahmed, Fahad Mashhour Alanezi, Turki M Alanzi, Davood Anvari, Seth Christopher Yaw Appiah, Muhammad Aqeel, Jalal Arabloo, Marcel Ausloos, Maciej Banach, Till Winfried Bärnighausen, Zulfiqar A Bhutta, Nicola Luigi Bragazzi, Vijay Kumar Chattu, Saad M A Dahlawi, Giovanni Damiani, Kebede Deribe, Samath Dhamminda Dharmaratne, Alireza Didarloo, Maysaa El Sayed Zaki, Arvin Haj-Mirzaian, Hadi Hassankhani, Claudiu Herteliu, Mehdi Hosseinzadeh, Mowafa Househ, Seyed Sina Naghibi Irvani, Jost B Jonas, Jacek Jerzy Jozwiak, Leila R Kalankesh, Naser Kamyari, Gbenga A Kayode, Md Nuruzzaman Khan, Khaled Khatab, Mona M Khater, Neda Kianipour, Yun Jin Kim, Dian Kusuma, Van Charles Lansingh, Mohammad Ali Mansournia, Francisco Rogerlândio Martins-Melo, Colm McAlinden, Walter Mendoza, Masoud Moghadaszadeh, Abdollah Mohammadian-Hafshejani, Shafiu Mohammed, Ahamarshan Jayaraman Nagarajan, Ionut Negoi, Cuong Tat Nguyen, Huong Lan Thi Nguyen, Bogdan Oancea, Andrew T Olagunju, Ahmed Omar Bali, Obinna E Onwujekwe, Adrian Pana, Vafa Rahimi-Movaghar, Kiana Ramezanzadeh, Reza Rawassizadeh, Abdallah M Samy, Masood Ali Shaikh, Kiomars Sharafi, Jasvinder A Singh, Wilma A Stolk, Bach Xuan Tran, Bhaskaran Unnikrishnan, Giang Thu Vu, Sanni Yaya, Naohiro Yonemoto, Chuanhua Yu, Arash Ziapour, and Simon I Hay.

Developing methods or computational machinery

Chris A Schmidt, Muktar Beshir Ahmed, Davood Anvari, Lucas Earl, Mehdi Hosseinzadeh, Mowafa Househ, Neda Kianipour, Masoud Moghadaszadeh, Shafiu Mohammed, Reza Rawassizadeh, Abdallah M Samy, Arash Ziapour, and Simon I Hay.

Providing critical feedback on methods or results

Victor Adekanmbi, Olatunji O Adetokunboh, Muktar Beshir Ahmed, Fahad Mashhour Alanezi, Turki M Alanzi, Vahid Alipour, Catalina Liliana Andrei, Tudorel Andrei, Davood Anvari, Seth Christopher Yaw Appiah, Jalal Arabloo, Mohammad Asghari Jafarabadi, Marcel Ausloos, Atif Amin Baig, Maciej Banach, Till Winfried Bärnighausen, Krittika Bhattacharyya, Zulfiqar A Bhutta, Ali Bijani, Oliver J Brady, Nicola Luigi Bragazzi, Zahid A Butt, Vijay Kumar Chattu, Saad M A Dahlawi, Giovanni Damiani, Feleke Mekonnen Demeke, Kebede Deribe, Samath Dhamminda Dharmaratne, Daniel Diaz, Maysaa El Sayed Zaki, Nataliya A Foigt, Masoud Foroutan, Richard Charles Franklin, Yuming Guo, Samer Hamidi, Hadi Hassankhani, Claudiu Herteliu, Tarig B Higazi, Mehdi Hosseinzadeh, Mowafa Househ, Olayinka Stephen Ilesanmi, Irena M Ilic, Milena D Ilic, Seyed Sina Naghibi Irvani, Ravi Prakash Jha, John S Ji, Jost B Jonas, Jacek Jerzy Jozwiak, Leila R Kalankesh, Naser Kamyari, Behzad Karami Matin, Salah Eddin Karimi, Gbenga A Kayode, Ali Kazemi Karyani, Ejaz Ahmad Khan, Md Nuruzzaman Khan, Khaled Khatab, Mona M Khater, Neda Kianipour, Yun Jin Kim, Soewarta Kosen, Dian Kusuma, Shanshan Li, Shokofeh Maleki, Mohammad Ali Mansournia, Francisco Rogerlândio Martins-Melo, Colm McAlinden, Walter Mendoza, Tomislav Mestrovic, Masoud Moghadaszadeh, Abdollah Mohammadian-Hafshejani, Seyyede Momeneh Mohammadi, Shafiu Mohammed, Mehdi Naderi, Ahamarshan Jayaraman Nagarajan, Ionut Negoi, Cuong Tat Nguyen, Huong Lan Thi Nguyen, Bogdan Oancea, Andrew T Olagunju, Ahmed Omar Bali, Obinna E Onwujekwe, Adrian Pana, Vafa Rahimi-Movaghar, David Laith Rawaf, Salman Rawaf, Reza Rawassizadeh, Aziz Rezapour, Ana Isabel Ribeiro, Abdallah M Samy, Masood Ali Shaikh, Eirini Skiadaresi, Shahin Soltani, Wilma A Stolk, Mu'awiyyah Babale Sufiyan, Alan J Thomson, Bach Xuan Tran, Khanh Bao Tran, Bhaskaran Unnikrishnan, Francesco S Violante, Giang Thu Vu, Tomohide Yamada, Sanni Yaya, Paul Yip, Naohiro Yonemoto, Chuanhua Yu, Yong Yu, Maryam Zamanian, Yunquan Zhang, Zhi-Jiang Zhang, Arash Ziapour, and Simon I Hay.

Drafting the work or revising it critically for important intellectual content

Chris A Schmidt, Muktar Beshir Ahmed, Catalina Liliana Andrei, Tudorel Andrei, Atif Amin Baig, Oliver J Brady, Felix Carvalho, Giovanni Damiani, Daniel Diaz, Maysaa El Sayed Zaki, Maha El Tantawi, Nazir Fattahi, Eduarda Fernandes, Nataliya A Foigt, Masoud Foroutan, Arvin Haj-Mirzaian, Mostafa Hosseini, Mowafa Househ, Olayinka Stephen Ilesanmi, Irena M Ilic, Milena D Ilic, Ejaz Ahmad Khan, Neda Kianipour, Carlo La Vecchia, Van Charles Lansingh, Paul H Lee, Tomislav Mestrovic, Masoud Moghadaszadeh, Shafiu Mohammed, Rahmatollah Moradzadeh, Paula Moraga, Kiana Ramezanzadeh, David Laith Rawaf, Salman Rawaf, Ana Isabel Ribeiro, Abdallah M Samy, Aziz Sheikh, Jasvinder A Singh, Eirini Skiadaresi, Mu'awiyyah Babale Sufiyan, Francesco S Violante, Maryam Zamanian, Arash Ziapour, and Simon I Hay.

Managing the overall research enterprise

Simon I Hay.

9.0 Acknowledgments

1150 **10.0 Competing interests**

1165   Resources for Health in the Republic of Rwanda under the President's Emergency Plan for AIDS Relief
1166   (PEPFAR)", University of Pennsylvania (UPenn) Population Aging Research Center (PARC) External
1167   Advisory Board Member; leadership role of the Global Health Hub Germany (initiated by the German
1168   Ministry of Health) as a co-chair; all outside the submitted work.

1169 R C Franklin reports a leadership or fiduciary role in board, society, committee or advocacy group, paid or unpaid,
1170   with the Australasian College of Tropical Medicine as the Honorary Treasurer and Vice President; outside the
1171   submitted work.

1172 C Herteliu and A Pana report grants or contracts from Romanian National Authority for Scientific Research and
1173   Innovation, CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084 (oct 2018-sep 2022)
1174   "Understanding and modelling time-space patterns of psychology-related inequalities and polarization" and
1175   project number PN-III-P2-2.1-SOL-2020-2-0351 (jun 2020-oct 2020) "Approaches within public health
1176   management in the context of COVID-19 pandemic", all outside the submitted work.

1177 J S Ji reports consulting fees paid directly from The World Bank Group; honoraria from the Chinese Preventive
1178   Medicine Association and China Center for Disease Control and Prevention National Institute of
1179   Environmental Health Science, outside the submitted work.

1180 J Jozwiak reports payments from Teva Pharmaceuticals, Amgen, Synexus, Boehringer Ingelheim, ALAB
1181   laboratoria, and Zentiva as personal fees outside the submitted work.

1182 A Sheikh reports a research grant to their institutions from Health Data Research UK outside the submitted work.

1183 J A Singh reports consulting fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field
1184   Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant
1185   consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice
1186   Point communications; and the National Institutes of Health and the American College of Rheumatology;
1187   payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events
1188   from Simply Speaking; support for attending meetings and/or travel from OMERACT, an international
1189   organization that develops measures for clinical trials and receives arm's length funding from 12
1190   pharmaceutical companies, when traveling to OMERACT meetings; participation on a Data Safety
1191   Monitoring Board or Advisory Board as a member of the FDA Arthritis Advisory Committee; leadership or
1192   fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with OMERACT as a
1193   member of the steering committee, with the Veterans Affairs Rheumatology Field Advisory Committee as a
1194   member, and with the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis as a
1195   director and editor; stock or stock options in TPT Global Tech, Vaxart pharmaceuticals, Atyu Biopharma,
1196   Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Inc., Seres Therapeutics and
1197   Charlotte's Web Holdings Inc. and previously owned stock options in Amarin, Viking, and Moderna
1198   pharmaceuticals; all outside the submitted work.

1199 W A Stolk reports grants or contracts from the Bill and Melinda Gates Foundation (BMGF) as an
1200   active member of the NTD Modelling Consortium (grant number OPP1184344); consulting
1201   fees from Mectizan Donation Programme as a member of the Mectizan Expert Committee
1202   (MEC) in the form of a small honorarium for participating in MEC meetings; all outside the
1203   submitted work.